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a protein deacetylase that was originally discoverd in a screening assay for longevity factors in yeast. It
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ZUSAMMENFASSUNG (DEUTSCH) 
Während Typ 1 Diabetes eine klassische Autoimmunerkrankung ist, sind sich die Fachleute uneinig, 
welche Rolle das Immunsystem im Typ 2 Diabetes spielt. Bisher nahm man an, dass die Hauptursache 
des Typ 2 Diabetes darin besteht, dass Insulin in den Zielorganen seine Funktion ungenügend 
ausführen kann. Es besteht eine sogenannte Insulinresistenz. Nun gibt es aber immer mehr 
Erkenntnisse, die dem Immunsystem auch im Typ 2 Diabetes eine bedeutende Rolle zuschreiben. 
Diese Dissertation ist in zwei Kapitel unterteilt. Das erste Kapitel widmet sich der Rolle von TLR2 im 
Typ 2 Diabetes. Dieser Rezeptor des Immunsystems erkennt und bekämpft eindringende Bakterien. 
Fette aus der Nahrung können TLR2 binden und aktivieren. Typ 2 Diabetiker sind häufig 
übergewichtig und haben daher ein erhöhtes Fettdepot. Da Übergewicht zu chronischen Entzündungen 
führen kann, könnte TLR ein molekulare Link zwischen der Fettleibigkeit und dem veränderten 
Blutzuckerhaushalt sein. Dies wird im ersten Kapitel dieser Dissertation untersucht. Die Hypothese 
wurde überprüft, indem Mäuse gemästet wurden. Danach wiesen sie eine erhöhte TLR Ausprägung 
vor. Unter anderem auch in Zellen, die mit Insulin interagieren, sowie in der Bauchspeicheldrüse 
(Pankreas), dem Produktionsorgan des Insulins. Diese übergewichtigen Mäuse hatten eine schlechtere 
Insulinsensitivität und Mühe, mit einem Zuckerschub umzugehen. Wurde der Versuch mit Mäusen 
durchgeführt, denen das TLR2 Gen fehlte (sogenannte Tlr2 −/− Mäuse), zeigte sich Interessantes: Das 
Insulin war wirkungsvoller, und sie konnten besser mit Zuckerschüben umgehen. Die gemästeten Tlr2 
−/− Mäuse waren etwa gleich schwer wie Kontrollmäuse, bei denen das TLR2 Gen vorhanden war, sie 
hatten jedoch eine gesündere Fettverteilung. Ihre Fettzellen waren kleiner und reagierten sensitiver auf 
Insulin. Zudem waren sie teilweise vor Leberschäden geschützt. Weiter waren ihre pankreatischen β-
Zellen (Insulinproduzenten) weniger entzündet und konnten mehr Insulin sezernieren. 
Zusammenfassend kann man sagen, dass Tlr2 −/− Mäuse teilweise von den ungesunden Folgen des 
Übergewichtes verschont blieben.  
Das zweite Kapitel beschäftigt sich mit SIRT1, einer Proteindeacetylase, die bei der Suche nach 
lebensverlängernden Faktoren in Hefe entdeckt wurde. SIRT1 ist bei verschiedensten biologischen 
Prozessen involviert. Es vermindert zellulären Stress, fördert die Entwicklung von spezialisierten 
Zellen und verbessert den Zuckerhaushalt sowie die Insulinsekretion von Mäusen. Das Interesse an 
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SIRT1 wurde geweckt, weil Angehörige einer Familie von Diabetikern eine Mutation im SIRT1 Gen 
tragen. Diese Punktmutation im Erbgut führt zu einem Austausch der Aminosäure Leuzin durch Prolin 
im SIRT1-Protein. Betroffene Familienmitglieder sind heterozygote Träger, das heisst: Neben der 
mutierten Form tragen sie auch ein gesundes Allel. Könnte die durch die Mutation beeinträchtigte 
Funktion von SIRT1 kompensiert werden, indem man das gesunde SIRT1 Allel mit chemischen 
Aktivatoren anregt? Zur Überprüfung dieser Hypothese wurden SIRT1 Aktivatoren (SRTs) an zwei 
verschiedenen Typ 1 Diabetes Tiermodellen getestet: an der non-obese diabetes (NOD) Maus und der 
multiple-low doses of streptozotocin (MLD-STZ) behandelten Maus. Entgegen den Erwartungen 
hatten die SRTs in keinem der beiden Tiermodelle positive Einflüsse. Zwei der SRTs lösten schwere 
Komplikationen aus, was zu mehreren Todesfällen führte. Die heterozygote Sirt1 +/− Maus wurde – im 
Gegensatz zu den Patienten, die auch nur ein gesundes SIRT1 Allel besitzen – nicht diabetisch. 
Wurden diese Mäuse mit MLD-STZ diabetisch gemacht, unterschieden sie sich nicht von Kontroll-
Sirt1 +/+-Mäusen. Schlussfolgernd kann gesagt werden, dass die Sirt1 +/−-Maus kein gutes Modell für 
die Diabetiker-Familie ist. Des Weiteren müssen SIRT1-Aktivatoren genauer untersucht werden, 
bevor besagte Familienangehörige damit behandelt werden könnten.  
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SUMMARY (ENGLISH) 
The involvement of the immune system and its mediators in the development of type 2 diabetes has 
been discussed controversially. While type 1 diabetes clearly is an auto-immune disease, type 2 
diabetes was believed to be caused mainly by insulin resistance, the inability of peripheral organs to 
properly use insulin. Lately, there is increasing evidence pointing to an important role of the immune 
system also in type 2 diabetes. 
This thesis is divided into two parts. Chapter 1 highlights the importance of TLR2, a receptor of the 
innate immune system, in the development of type 2 diabetes. TLR2 recognizes structural parts of 
intruding bacteria and helps to destroy invading pathogens. TLR2 can also be activated by dietary fatty 
acids and studies in humans and animal models have shown that obesity leads to chronic low grade 
inflammation. Therefore, this part of the thesis investigates if TLR2 is a  molecular link between 
increased dietary lipid intake and the impaired regulation of glucose homeostasis. HFD fed mice 
showed increased expression of certain Tlrs in different cell types, including insulin-sensitive tissues 
and pancreatic islets. Compared to their wild-type littermates, Tlr2 −/− mice on a HFD displayed 
improved glucose tolerance and increased insulin sensitivity. Despite similar total body weight, these 
mice had reduced perigonadal fat pad weight, in addition to having smaller adipocytes that displayed 
improved insulin-stimulated glucose uptake. Tlr2 −/− mice were also protected from HFD-induced liver 
insulin resistance, hepatosteatosis and liver inflammation. Further, β-cell insulin secretion was 
improved and pancreatic islet inflammation was reduced in HFD fed Tlr2 −/− mice compared to wild-
type controls. Overall, Tlr2 −/− mice were protected from insulin resistance and β-cell dysfunction 
induced by a HFD. 
Chapter 2 deals with SIRT1, a protein deacetylase that was originally discoverd in a screening assay 
for longevity factors in yeast. It was found to be involved in manifold actions such as genomic 
stability, stress resistance and metabolic regulation, improvement of glucose homeostasis and insulin 
secretion. SIRT1 attracted attention when a family of type 1 diabetics was investigated. Affected 
family members heterozygously carry a point mutation in SIRT1, leading to a leucine to proline 
exchange in the SIRT1 protein (L107P). The aim of this study was to evaluate if activation of the 
SIRT1 enzyme derived from the wild-type allele could be  a safe and efficient way to medicate these 
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patients. SIRT1 activators (SRTs) were applied to two different animal models of type 1 diabetes, the  
non-obese diabetes (NOD) mouse and the multiple-low doses of streptozotocin (MLD-STZ) treated 
mouse. In contrast to what was expected, in both models SRTs were unable to delay the onset of 
diabetes. The amount of pancreatic immune cell infiltration (insulitis score) was also not different 
between SRT treated NOD and control NOD mice. Importantly, two SRTs caused severe side effects, 
leading to an accumulation of cases of death in these treatment groups. Further, Sirt1 +/− mice did not 
develop auto-immune diabetes and the development of diabetes was not different in Sirt1 +/− mice 
compared to Sirt1 +/+ when treated with MLD-STZ. In summary, the Sirt1 +/− mouse was not a suitable 
model for the L107P familial diabetes and further evaluations of SIRT1 activators are needed before 
they can be recommended to treat the affected family members.  
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BMDM bone-marrow-derived macrophage 
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i.p. intra peritoneal 
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Mcad medium-chain acyl dehydrogenase 
MCP monocyte chemotactic protein 
MIP macrophage inflammatory protein 
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PCR polymease chain reaction 
Pgc peroxisome proliferator-activated receptor gamma coactivator 
RNA 
SEM 
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standard error of the mean 
SIRT1 sirtuin (silent mating type information regulation 2 homolog) 1 
TLR toll-like receptor  
TNF tumor necrosis factor 
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1  INTRODUCTION 
 
1.1 Glycaemic control 
 
The human body needs fuel to operate properly. The utilisation of energy is manifold: exercise moves 
us, anabolic and catabolic processes constantly remodel our body, organs fulfil their specific task and 
the brain integrates information and manages the complex coordination of actions. This performance 
requires a constant supply of energy which is mainly taken up by food ingestion. The body’s primary 
source of energy is glucose. A tight glycaemic control is crucial to maintain functionality at all times. 
Hypoglycaemia (low glucose) may interrupt important biological processes, harm the brain and even 
lead to life-threatening situations while hyperglycaemia (high glucose) may cause microvascular 
damage (e.g. retinopathy), macrovascular damage (e.g. coronary heart disease) and other diabetes 
related complications. Therefore, blood glucose must always be kept between 2.5 and 5 mmol/l, 
independent of organ activities. This is mainly achieved by two pancreatic hormones, namely the 
anabolic insulin and its catabolic antagonist glucagon [1], even though steroids, catecholamines, 
growth hormones and others also play important roles. The main stimulant for insulin release is 
glucose itself. After food ingestion, blood glucose (coming from the ingested food) rises, which 
triggers insulin secretion from pancreatic β-cells. As a consequence plasma insulin rises, commanding 
organs to take up glucose, which lowers blood glucose concentration and brings it back to a normal 
range. Glucagon is the other major player that keeps euglycaemia. Its main stimulus is low glucose. In 
many ways it antagonizes the action of insulin, mainly by stimulating glucose release from the liver, 
resulting in increased blood glucose concentration.  
 
1.2 The history of diabetes mellitus and the discovery of insulin 
 
It was as early as in ancient Greece that the phenomenon of sick people that excessively urinated 
“sweet urine” was described. The Greeks named this sickness diabetes (“to straddle”), a reference to 
the fact that people suffering from diabetes often urinated. In 1675 the Latin word mellitus (“honey”) 
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was added, owing to the sweet taste of urine from diabetics. Suffering from diabetes mellitus was an 
almost certain death sentence with people getting weaker and weaker and finally dying of acidosis. In 
1889 Oskar Minowski and Joseph von Mering from the University of Strasbourg identified the organ 
that was involved in the development of diabetes mellitus. They removed the pancreas from a dog and 
several days later they detected sugar in the dog’s urine, resembling symptoms of diabetic humans. An 
important step towards the treatment of diabetes mellitus was achieved in 1921, when Frederik 
Banting and Charles Best from the University of Toronto repeated the experiments of Minowski and 
von Mering, and in addition “cured” the pancreatectomized dog by reinjecting a lysate derived from 
the removed pancreas. Only two months later, on January 11th 1922, a young diabetic man was 
injected with “insulin”, lowering his blood glucose significantly. Banting and Best received the Nobel 
Prize for the discovery of insulin in 1923. For treatment of diabetics, insulin was harvested from beef 
and pork and only in 1980 recombinant human insulin was produced by the U.S. biotech company 
Genentech. In the meantime (1953), the complete amino acid sequence of insulin was determined by 
Frederick Sanger [2, 3] for which he received the first of his two Nobel Prizes. 
Decades of research have yielded several approaches to treat diabetes. An important effort was the 
development of modified insulin which allows to adjust the rate at which insulin is metabolized by the 
body. Several supporting substances are in clinical use. Insulin secretagogues (e.g. sulfonylureas) 
trigger insulin release by the β-cells, insulin sensitizers (e.g. metformin, glitazones) amplify the 
actions of insulin and incretin mimetics (e.g. GLP-1, GIP, DPP-4 inhibitor) use other routes to 
ameliorate insulin secretion. Anti-diabetic drugs became a lucrative market for pharmaceutical 
companies and with the expected increase in patient numbers over the next decades research will be 
intensified and hopefully yield new exciting ways to treat this disease.  
 
1.3 The pancreas and its hormones 
 
In the abdomen, between the duodenum and the stomach lies the 15-20 cm long pancreas, wedge-
shaped and 70-100 g in weight. It contains two types of tissue: the endocrine part which secretes 
hormones into the blood, and the exocrine part which secretes digestive enzymes into the gut. 
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1.3.1   The endocrine pancreas 
 
Around 2 % of the pancreas account for the endocrine glands, called the islets of Langerhans. These 
clusters of cells range in cell number from a few cells to thousands of cells with a diameter of up to 
300-400 µm [4].  The human pancreas contains about 1 million islets of Langerhans and consists of 5 
types of cells that produce hormones such as insulin (β-cells, 65-80% of total islet cells), glucagon (α-
cells, 15-20%), somatostatin (δ-cells, 3-10%), pancreatic polypeptide (PP cells, 3-5%), and ghrelin (ε-
cells, <1%) [5]. 
The pancreatic islets are highly vascularized [6] allowing them to sense endocrine signals and to fine-
tune hormone release into the bloodstream. The direction of blood flow is physiologically important, 
because hormones secreted from one cell type could act downstream in a paracrine fashion on other 
cell types (e.g. glucagon secreted by α-cells is a potent insulin secretagogue, somatostatin from δ-cells 
inhibits insulin secretion). In rodents the blood flows in a defined order,  BAD (β - α - δ), restricting β-
cells to sense circulating, but not paracrine hormones [7]. Structure and composition of human and 
rodent islets differ [8, 9], which needs to be taken into account when comparing experimental data of 
humans and rodents. Early reports described a simple core-mantle architecture in human islets, similar 
to that of rodent islets. Other publications claim that all subtypes of cells are dispersed throughout the 
human islet [4, 9] and/or that they might be organized in β-cell clusters surrounded by α-cells [10, 11]. 
A recent paper also scanned human islets three dimensionally and proposes a three layer model, where 
an enriched β-cell layer is sandwiched between two α-cell enriched layers [12] (Fig. 1). However, 
there is a general agreement that the proportion of β-cells to α-cells is smaller in human islets 
compared to rodent islets [9, 13, 14]. 
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Fig. 1   Architecture of pancreatic islets. (A) Schematized model of human islets where a β-cell (red) layer is 
sandwiched by two α-cell layer (green). This thick layer is lined with vessels (blue) at both sides and is folded to 
form islets (B) [12]. Sections of human (C) and rat (D) adult pancreas stained for insulin (red) and glucagon 
(green). Graph adapted from [15].  
 
1.3.2   The exocrine pancreas 
 
The vast majority of the pancreas is exocrine tissue, comprised of acinar cells, ductal cells and goblet 
cells. Exocrine cells are specialized in the production and secretion of precursors and mature enzymes 
required for digestion. Each day, the human pancreas produces approximately 1.5 l of pancreatic juice 
containing proteases (to hydrolyze proteins), amylases (to digest carbohydrates), lipases (to 
breakdown lipids) and nucleases (to digest nucleic acids).  
Acinar cells are epithelial cells containing digestive enzymes that are released upon neuronal or 
humoral stimulation. Duct cells are also epithelial cells and secrete HCO3-, which aids the micellar 
solubilzation of lipids. The third type of cell found in the exocrine pancreas are goblet cells. They are 
mainly found in the large, distal pancreatic ducts and produce mucin. 
 
 
 
 
C D 
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1.4   Insulin gene, synthesis and secretion in β-cells 
 
In 1953 Frederick Sanger published the complete sequence of insulin [2, 3] for which he was awarded 
with the nobel prize. In humans, the insulin gene is located on the short arm of chromosome 11 [16, 
17], spans three exons and two introns and is translated into a 5.8 kDa molecule containing two chains. 
These two chains, the 21 amino acid long A chain and the 30 amino acid long B chain, are linked by 
two disulfide bonds. Several tissue specific transcription factors (e.g. Pdx-1, BETA2/NeuroD, Pax-6) 
lead to β-cell differentiation and expression of insulin [18]. In addition, insulin is also expressed in the 
pituitary gland [19] which needs to be taken into consideration when the promoter of the insulin gene 
is used to create β-cell specific transgenic mice (e.g. rip-cre). 
The mature mRNA of the insulin gene contains sequences encoding several peptide domains, called 
preproinsulin. This precursor is translated in the rough endoplasmatic reticulum, where the leader 
sequence is cleaved off, giving rise to proinsulin [20, 21]. Proteases in the trans-Golgi cleave the 
proinsulin at two sites, which leads to the mature insulin molecule and an equimolar amount of C 
peptide, which are stored in secretory granules for later exocytosis [22-24].  
The main trigger for insulin release in the β-cell is glucose [22], which is transported from the blood 
into the β-cells via the glucose transporter (GLUT). GLUT-1 is the main glucose transporter in 
humans, while rodent β-cells predominantly express GLUT-2 [25]. Glucokinase phosphorylates 
glucose which eventually leads to NADH (and ATP, pyruvate), which is used in the TCA cycle in 
mitochondria to build up a H+ gradient. This leads to production of  ATP from ADP in the cytosol. 
ATP-sensitive K+ channels react to this increase in ATP/ADP ratio, close and subsequently lead to a 
depolarization of the cell membrane. Voltage-dependent Ca2+ channels open and the raise in cytosolic 
Ca2+ concentration leads to fusion of the insulin-containing granules with the plasma membrane. In a 
first rapid reaction, stored insulin is released (first phase insulin) which is followed by a bigger release 
of preformed and newly synthesized insulin (second phase insulin) [26] (Fig. 2). 
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Fig. 2   First and second phase insulin. (A) An intravenous glucose tolerance test leads to a distinct first and 
second phase peak of insulin released into the circulation. (B) In a diabetic individual, the β-cells have lost their 
function and do not show any reaction to an oral glucose load. Graph adapted from [27]. 
 
1.5   Insulin function and target tissues 
 
The primary function of insulin is to lower blood glucose by acting on enzymes in insulin sensitive 
tissues, namely the liver, muscle and fat. 
In the liver, insulin promotes the storage of glucose as glycogen. This is achieved by regulating the 
enzymes that are involved in glycogenesis and glycogenolysis. First, insulin enhances the transcription 
of glucokinase and glycogen synthase, two key enzymes involved in the transformation of glucose to 
glycogen. Second, insulin suppresses the transcription of glycogenolysis enzymes, namely glucose-6-
phosphatase and glycogen phosphorylase. In addition, insulin stimulates lipogenesis and protein 
synthesis and inhibits gluconeogenesis, all leading to lower blood glucose concentrations. 
In the muscle, insulin promotes the uptake of glucose and its storage as glycogen. As in the liver, 
insulin activates glycogen synthase. Hexokinase, the liver specific enzyme that converts glucose to 
glucose-6-phosphate, is also induced by insulin. In addition, insulin stimulates protein synthesis and 
the recruitment of GLUT-4, which translocates from an intracellular pool to the muscle membrane 
where it facilitates the diffusion of glucose into muscle cells. Note that in comparison to the non-
insulin sensitive GLUT-2 in liver, GLUT-4 in muscle (and fat) is positively regulated by insulin [25]. 
B A 
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In adipocytes, insulin promotes the uptake of glucose and its storage as triglycerides. It increases 
glycolysis and triggers the conversion of pyruvate to free fatty acids by enhancing the transcription of 
pyruvate dehydrogenase and acetyl CoA carboxylase. In addition, insulin stimulates the esterification 
of α-glycerol-phosphate with free fatty acids to form triglycerides and inhibits the enzyme of the 
reverse reaction, hormone-sensitive triglyeride lipase. As in the muscle, GLUT-4 is recruited to the 
plasma membrane upon insulin stimulation.  
 
1.6   Glucagon and its function 
 
A major hormone that counteracts the blood glucose lowering effects of insulin is glucagon. It 
prevents hypoglycaemia by increasing hepatic glucose output [28, 29]. Glucagon acts on the liver by 
increasing glycogen breakdown (glycogenolysis) and de-novo synthesis of glucose (gluconeogenesis), 
and decreasing the rate of glucose catabolism (glycolysis). The glucagon precursor proglucagon is 
expressed in pancreatic α-cells, intestinal L-cells and in hindbrain neurons [30]. The prohormone 
convertases (PC) differentially process proglucagon.. PC2 is found in α-cells and converts 
proglucagon to glucagon. Contrarily, L-cells and neurons in the hindbrain express PC3/PC1 which 
converts proglucagon to glucagon-like-peptide (GLP)1 and GLP2 [30-32]. The major glucagon 
secretagogues are ingestion of protein (even though glucagon acts on carbohydrates and not protein), 
hypoglycaemia, circulating epinephrine, neuronal stimulation and crosstalk between α-cells and β-
cells. Glucagon binds to the glucagon receptor, a G-protein coupled receptor, and signals through the 
second messenger adenosine 3’,5’-cyclic monophosphate (cAMP) and phospholipase C (PLC) / 
inositol triphosphate (IP3) pathway to exert its hyperglycaemic action.  
 
1.7   Somatostatin, pancreatic polypeptide and ghrelin 
 
The human endocrine pancreas comprises of 5 cell types. The two most important – insulin producing 
β-cells and glucagon producing α-cells – were discussed above. The three remaining cell types are δ-
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cells (produce somatostatin, 3-10%), ε-cells (produce ghrelin, <1%), and PP cells (produce pancreatic 
polypeptide (PP), 3-5%) [5]. 
Somatostatin is produced in pancreatic δ-cells, intestinal D-cells and in the hypothalamus. Its main 
function is to inhibit the secretion of hormones like thyroid-stimulating hormone (TSH), gastrin and 
growth hormone (GH). In addition, it also inhibits the secretion of insulin and glucagon [33]. Ghrelin 
was first described in 1999 as a growth hormone-releasing peptide [34]. It is produced in pancreatic ε-
cells, in the fundus of the stomach and in certain areas of the brain [35]. It seems to promote hunger by 
acting on the hypothalamus [36], opposing leptin. Pancreatic polypeptide is post-prandially secreted in 
pancreatic PP-cells [37-39] and seems to be involved in weight loss, as injection [40, 41] or β-cell 
specific genetic over-expression [42] of PP in ob/ob mice reduces bodyweight by decreasing food 
intake and increasing energy expenditure. PP infusion studies in humans have shown that food intake 
is reduced in patients with the Prader-Willi syndrome [43] (patients display higher levels of PP) and in 
healthy individuals [44, 45]. 
 
1.8   Diabetes mellitus  
 
Diabetes mellitus is a metabolic disease characterized by high concentrations of blood glucose 
resulting from diminished insulin production and/or attenuated biological insulin action. 
Hyperglycaemia and consequently advanced glycation end-products (AGE) in endothelial cells, 
alterations in the microarchitecture of cells and its components, induction of inflammation and other 
cellular adaptations may lead to severe consequences, ranging from peripheral neuropathy (nerve 
damage), retinopathy (damage of the retina in the eye), nephropathy (kidney damage), to increased 
risk for cardio- and cerebrovascular diseases [46]. The first diabetic patient was treated in 1922 (see 
1.2 The history of diabetes mellitus and insulin) and according to a survey published by the World 
Health Organisation (WHO) 2.8% of the earth's population had diabetes in the year 2000 and this 
number will almost double by 2030 [47]. This corresponds to 366 million people worldwide [48, 49]. 
According to data from the 2007 National Diabetes Fact Sheet, 7.8% of the population in the United 
States (23.6 million) have diabetes. The major risk factors that contribute to this epidemic of diabetes 
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are inactivity, unbalanced diets, obesity and genetic predisposition. The dramatic increase in the 
diabetes incident rate may be explained by the more and more sedentary lifestyle, elevated food 
consumption and changed age pattern in our society. 
The traditional classification system distinguishes several distinct subtypes of Diabetes mellitus, 
although there is evidence for overlaps [50, 51] . The vast majority of diabetics belong to the type 2 
diabetes mellitus group which is associated with insulin resistance and relative insulin deficiency, 
while less people suffer from type 1 diabetes mellitus which is characterized by autoimmune β-cell 
destruction and subsequent absolute insulin deficiency. Other classifications include gestational 
diabetes and prediabetes, a state characterised by elevated blood glucose levels that are higher than 
normal but not yet high enough to be diagnosed with overt diabetes. 
 
1.8.1   Type 1 diabetes mellitus 
 
Type 1 diabetes mellitus (T1DM) accounts for 5-10 % of all cases of diabetes. In this disease, 
autoimmune destruction of the insulin producing β-cells leads to absolute insulin deficiency. The 
absence of insulin increases the balance between produced (liver) and used (muscle) glucose and 
ketones. Glucose excess leads to osmotic diuresis in the kidney and the subsequent dehydration and 
accumulated acidosis finally leads to death from diabetic ketoacidosis.  
T1DM patients display antibodies against their own β-cells, insulin, and other islet specific proteins, 
accompanied by immune cell infiltration into the pancreas [52-54].  Islets are smaller, islet volume and 
mass are decreased [55, 56], and β-cells are diminished or absent [55]. The pathology of T1DM is not 
completely understood, but the interaction of environmental factors (such as viral infections, stress, or 
toxins) and T1DM susceptibility gene variants [56] seems to trigger diabetes in genetically susceptible 
individuals [46, 57].  
Insulin replacement therapy is used to treat T1DM. In advanced stages of the disease, organ 
transplantation (whole pancreas or purified islets) are also applied to increase insulin production and 
normalize blood glucose concentrations.  
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1.8.2   Type 2 diabetes mellitus 
 
Type 2 diabetes mellitus (T2DM) accounts for 90-95 % of all cases of diabetes. T2DM patients 
display peripheral insulin resistance, thus higher concentrations of insulin are required to exert the 
same magnitude of glucose disposal in muscle and adipocytes, and to inhibit glucose output in the 
liver to the same extent as in healthy individuals. Only 10 % of people which are insulin resistant are 
diabetic [58], because the increased demand for insulin is compensated by increased insulin 
production. This is achieved by enlarging both islet mass and β-cell function [59]. The major cause of 
insulin resistance is obesity and aging [60]. Caloric excess leads to hypertrophy of adipocytes and a 
changed adipokine secretory profile. Nutrient overload, increased fatty acid flux and inflammation 
induce insulin resistance [60-62]. T2DM patients show impaired GLUT4 translocation in skeletal 
muscle [63], corrupted ability of insulin to phosphorylate insulin receptor substrate (IRS) in skeletal 
muscle [64] and adipocytes [65] and decreased expression of insulin receptors on hepatocytes [66]. 
The progression to T2DM develops in a biphasic pattern. First, the pancreatic β-cell mass increases in 
response to the increased insulin demand, which was observed in obese non-diabetic or pregnant 
individuals. As the need for insulin progressively increases, the β-cells not only fail to adapt further 
but also undergo apoptosis, which leads to insulin deficiency and diabetes [67] (Fig. 3). 
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Fig. 3   Initiation of type 2 diabetes. Increased insulin demand triggers the upregulation of β-cell mass (green 
spheres). As insulin demand rises even more, the pancreatic β-cell mass fails to adapt, which leads to relative 
insulin deficiency and diabetes. Adapted from [50]. 
 
It is not quite clear why β-cells of a T2DM patient fail and undergo apoptosis. It was proposed that 
production of reactive oxygen species, endoplasmatic reticulum stress, dyslipidemia, accumulation of 
islet associated polypeptide (IAPP) and induction of Fas and IL-1β contribute to the destruction of β-
cells [68-70]. Obese individuals display an increased inflammatory profile, originating from 
adipokines and chemokines/cytokines released by infiltrating macrophages and dendritic cells [71]. 
This chronic, low-grade inflammation can cause insulin resistance [72] and β-cell dysfunction [69]. 
T2DM patients have an increased number of islet-associated macrophages [73] which was also 
observed in various animal models, where HFD feeding and excessive obesity (db/db mice) display 
pancreatic immune cell infiltration [73, 74]. Recently, blocking inflammation in T2DM has 
successfully been implemented in clinical trials. Administration of the naturally occurring IL-1β 
receptor antagonist (IL-1Ra) or neutralizing IL-1β antibodies reduces islet inflammation and improves 
β-cell function in vivo [75-77].  
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2  TLR2-DEFICIENT MICE ARE PROTECTED FROM INSULIN 
RESISTANCE AND β-CELL DYSFUNCTION INDUCED BY A HFD 
 
2.1   Introduction 
 
2.1.1   TLRs 
 
Toll-like receptors (TLRs) are widely expressed transmembrane receptors of the innate immune 
system, recognizing patterns of invading pathogens [78]. Eleven human TLRs and thirteen mouse 
TLRs have been identified so far. They are activated by lipids, carbohydrates, nucleic acids and 
proteins [79-81]. Upon stimulation, TLRs trigger inflammation mainly via NFκB (but also via AP1, 
IRF3/7 and other signalling cascades) and therefore help to destroy invading pathogens. This 
destructive mechanism is essential to keep cellular homeostasis, but might also lead to collateral tissue 
damage. Especially prolonged TLR activation may lead to a chronic low grade inflammation and may 
support the development of chronic diseases like alzheimer’s disease, atherosclerosis, diabetes and 
cancer [82-85]. This is supported by the findings that TLRs and their ligands are elevated in 
inflammatory diseases and that blocking TLR pathways by either knocking out certain TLRs or the 
TLR adaptor protein myeloid differentiation primary response gene 88 (MyD88), protects against the 
development of inflammatory diseases in animal models [86-88]. Since TLRs are not ligand-specific 
and instead recognize general patterns of bacteria, fungi and viruses, they are also activated by 
structurally similar patterns of non-pathogens, such as dietary lipids [89, 90]. Nutritional fatty acids, 
such as palmitate and oleate, were shown to activate TLR4 which triggered inflammation in vivo and 
lead to insulin resistance in mice on a HFD [90]. These findings support a role for TLRs in fuel 
mediated chronic inflammatory diseases and link obesity with T2DM. 
 
2.1.2   TLR2 
 
A broad range of TLR2 receptor activators have been described, including components of bacterial 
cell walls, such as lipopolysaccharides (LPS), lipoproteins and glycoproteins, zymosan, peptidoglycan 
and other lipid based structures. TLR2 is predominantly expressed in immune cells but is also found in 
other tissues, including insulin sensitive adipocytes, hepatocytes and myocytes [91, 92]. TLRs signal 
through several adaptor molecules, but TLR2 primarily depends on the MyD88 pathway [93]. TLR2 
activation via binding of ligands recruits MyD88, which in turn triggers NFκB-associated genes that 
encode proinflammatory cytokines such as TNFα and Il-6. 
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2.1.3   TLR2, obesity and inflammatory diseases  
 
Recent studies have shown that non-essential fatty acids, including palmitate and oleate, can activate 
TLR2 signalling to induce proinflammatory cytokine production, leading to tissue-specific 
impairments and insulin resistance [89, 90, 94-96]. Chronic activation of the innate immune system is 
associated with type 2 diabetes, and evidence suggests that both insulin resistance and β-cell failure 
are promoted by low grade inflammation in humans [97-99]. Animal models of type 2 diabetes also 
show increased levels of cytokines, chemokines and immune cells in both insulin-responsive tissues 
(liver, muscle, adipose tissue) and pancreatic islets [73, 97, 100-102]. This local tissue inflammation 
has been causally linked to insulin resistance and β-cell function [97, 102]. Genetic ablation studies in 
HFD models have shown that pro-inflammatory CD11c+ cells are responsible for the induction of 
inflammation in insulin sensitive tissues and thereby impact on insulin sensitivity [103]. Similar 
results were obtained in human studies, where T2DM patients treated with salicylate (NF-κB inhibitor) 
displayed improved insulin sensitivity [76, 104]. In another study, T2DM patients were treated with 
the IL-1 receptor antagonist IL-1Ra which improved β-cell insulin secretion [75].  
Several observations point to TLR2 as a important bridge between obesity, inflammation and diabetes. 
First, obese humans and rodents have a gram-positive bacteria enriched microbial flora [105] and 
therefore  possibly increased TLR2 signalling. Second, TLR2 was shown to be involved in the 
development of palmitate-induced insulin resistance in myotubes [95]. Third, TLR2 knockout mice 
showed improvements in the metabolic syndrome associated with HFD-induced obesity [90, 106-108]. 
Fourth, inactivating TLR2 with siRNA improved insulin sensitivity in HFD-fed mice [109]. Finally, 
HFD-fed Tlr2 −/− mice showed improvements in the metabolic syndrome relative to HFD-fed wild type 
mice [106], even though the underlying mechanisms are not completely understood. 
 
2.1.4   Aim of the thesis, TLR2 part 
 
TLR2 recognizes structural parts of intruding gram-positive bacteria [78], triggers inflammation via 
NFκB and  helps to destroy the invading pathogen. Recently, it has been shown that TLR2 can also be 
activated by dietary fatty acids [89]. Given the fact that TLR2 was also shown to be involved in the 
induction of insulin resistance in myotubes in vitro [95], we decided to investigate the involvement of 
TLR2 in diet-induced obesity and diabetes in animal models of T2DM. 
Hypothesis 1:  TLR2 is expressed on pancreatic β-cells and is a molecular link between 
increased dietary lipid intake and the regulation of insulin. 
Hypothesis 2: Blocking TLR2 in vivo protects from the adverse effects of HFD-induced obesity.  
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2.2   Methodology 
 
2.2.1   Animals 
 
Tlr2 −/− mice (strain B6.129-Tlr2 tm1Kir/J, the Jackson Laboratory, Bar Harbor, ME, USA) backcrossed 
on C57BL/6J for four to five generations were bred in house with C57BL/6J mice to generate all Tlr2 
+/+ and Tlr2 −/− sex- and age-matched littermate mice used for in vitro and in vivo studies. To determine 
the genetic purity of Tlr2 +/+ and Tlr2 –/– mice, we genotyped 112 microsatellite markers evenly 
distributed across the whole mouse genome. This confirmed that 93–95% of the genome of Tlr2 +/+ 
and Tlr2 –/– littermate mice used in this study was derived from B6. Db/wt mice (strain B6.Cg-
Dock7<m> +/+ Lepr<db>/J, the Jackson Laboratory, Bar Harbor, ME, USA) were bred in house with 
Tlr2 +/- mice to generate all db/db Tlr2 +/+ and db/db Tlr2 −/− sex- and age-matched littermate mice used 
for in vivo studies. Animals were housed under specific-pathogen-free conditions at the Institute of 
Labortierkunde, Vetsuisse faculty of the University of Zürich (Zürich, Switzerland). Experiments were 
performed according to Swiss veterinary law and institutional guidelines. The committee for animal 
welfare at the Katholieke Universiteit Leuven approved all tissue isolation protocols from mice used 
for TLR2 tissue expression profiling. 
 
2.2.2   Tissue expression of TLR2    
 
The gene array was performed in collaboration with the laboratory of Dr. Frans C. Schuit at the 
Department of Molecular Cell Biology, Gene Expression Unit, Katholieke University in Leuven, 
Belgium. RNA from whole tissues were extracted using TRIzol (Invitrogen, Basel, Switzerland), 
followed by a cleanup with RNeasy columns (Qiagen, Hombrechtikon, Switzerland). RNA was 
reverse transcribed into cDNA (SuperScript Choice System, Invitrogen, Basel, Switzerland) using 
oligo-dT primers and a T7 RNA polymerase promoter site. cDNA was in vitro transcribed and biotin-
labelled (Affymetrix IVT labeling kit, Santa Clara, CA, USA). Quantity and quality of total RNA and 
cRNA profiles of all RNA preparations were analyzed using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA) and 2100 Bioanalyzer (Agilent, Santa Clara, CA, 
USA). Quantification of mRNA was performed using Affymetrix mouse 430A 2.0 expression 
microarrays. The overnight biotin-labelled cRNA was fragmented during 35 min at 94°C and 
hybridized during 16 hours at 45°C, followed by washing/staining in a Fluidics Station and scanning 
using a GeneScanner 3000 (both Affymetrix, Santa Clara, CA, USA). Raw data were analyzed using 
GCOS software (Affymetrix, Santa Clara, CA, USA). Signal intensities were scaled using the global 
scaling method taking 150 as target intensity value. 
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2.2.3   Metabolic studies    
 
Animals were fed a HFD containing 58, 26 and 16 cal/cal from fat, carbohydrate and protein, 
respectively, and a total of 23.2 kJ/g (Diet D12331, Research Diets, New Brunswick, NJ, USA) 
whereas the control diet contained 29, 39 and 32 cal/cal from fat, carbohydrate and protein, 
respectively, and a total of 11.7 kJ/g (Provimi Kliba AG, Kaiseraugst, Switzerland). For GTT, mice 
fasted for 12h (19:00 – 7:00) were injected i.p. with 2 mg/g body weight glucose and insulin was 
measured by ELISA (Mercodia, Uppsala, Sweden). ITT was performed by injecting female mice 
starved for 3h (8:00 – 11:00) i.p. with 0.85 U/kg human insulin (Novo Nordisk, Denmark), and male 
mice i.p. with 1.0 U/kg insulin. Pam2CSK4 (5 μg/mouse) dissolved in saline or saline was injected i.p. 
into Tlr2 +/+ and Tlr2 –/– mice, and after 24 h plasma was analysed for serum amyloid A by ELISA 
(Invitrogen, Basel, Switzerland). 
 
2.2.4   Isolated adipocyte experiments    
 
White adipocytes were isolated by collagenase digestion, filtered through a 250 µm nylon mesh and 
washed twice in Krebs buffer. To determine glucose incorporation, adipocytes were incubated with D-
[U-14C]glucose (final glucose concentration, 0.89 mmol/l) for 60 minutes in the presence or absence of 
100 nM insulin. Glucose incorporation was stopped by centrifuging the mixture in a  phthalic acid 
dinonyl ester gradient, which allows to separate the adipocytes from the medium due to their different 
specific weight. The adipocyte layer was then subjected to liquid scintillation counting. Aliquots of 
adipocyte fractions were used to determine mean cell diameters. Photographs of isolated adipocytes in 
the hemocytometer were taken, and images were analyzed using  ImageJ software (National Institue of 
Health, Bethesda, MD, USA) for quantification (http://rsbweb.nih.gov/ij/). At least 120 adipocytes per 
mouse were analyzed. 
 
2.2.5   Indirect calorimetry and physical activity   
  
Mice were placed in airtight respiratory cages that were continuously ventilated with a flow rate of 0.5 
l/min to measure oxygen consumption (VO2) and carbon dioxide production (VCO2). For each cage, 
air was sampled for 30 s at 5 min intervals. Energy expenditure was calculated according to [110] 
using the following equation: total energy expenditure (kcal/h/kg) = 3.9 x VO2 l/h + 1.1 x V.O2 l/h. 
RQ was defined as VCO2 (l)/ VO2 (l). Data were analysed with AccuScan Integra ME software 
(AccuScan Inc., Columbus, OH, USA). After allowing animals to adapt to metabolism cages for 5 
days, mice were i.p. implanted with a telemetry sensor (TA-F20) (Data Science International, St Paul 
MN, USA) under brief anaesthesia. The mice were allowed to recover for at least 1 week. Physical 
activity was measured every 5 min using Dataquest A.R.T. 3.1 software (Data Science International). 
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2.2.6   Plasma analysis 
 
Plasma samples were assayed using mouse Luminex kits (Millipore, Billerica, MA, USA) according to 
the manufacturer’s instruction. NEFAs, cholesterol and ketone bodies in plasma was analysed using 
colorimetric assays following the manufacturer’s instructions (Wako, Richmond, VA, USA). 
Triacylglycerols were determined using a GPO-Trinder-based serum triacylglycerol kit from Sigma 
(St Louis, MO, USA).  
 
2.2.7   Glucose clamp studies    
 
Mice were anesthetized with isoflurane, and a catheter (MRE 025, Braintree Scientific, Braintree, MA, 
USA) was inserted into the left jugular vein and exteriorized at the back of the neck. After 7 days of 
recovery, only mice that had regained greater than 95% of their preoperative weight were studied. 
After a fasting period of 5 hours, 3-[3H]glucose (0.1 µCi/min; PerkinElmer, Waltham, MA, USA) was 
infused for 80 minutes, and blood was collected from tail tip for basal turnover calculation. After basal 
sampling, insulin (18 mU/kg/min) was infused for 2 hours. Euglycaemia was maintained by 
periodically adjusting a variable infusion of 20% glucose with a syringe pump (TSE Systems, 
Chesterfield, MO, USA). The glucose infusion rate was calculated as the mean of the steady-state 
infusion (60–90 minutes) after 1 hour of insulin infusion. A blood sample was collected from tail tip 
after steady-state infusion. The glucose turnover rate was calculated by dividing the rate of 3-
[3H]glucose infusion by the plasma 3-[3H]glucose–specific activity. Hepatic glucose production was 
calculated by subtracting the glucose infusion rate from the glucose turnover rate.  
 
2.2.8   Total liver lipid extraction  
   
Liver tissue (30 mg) was homogenized in PBS, and lipids were extracted in a chloroform/methanol 
(2:1) mixture. Total liver lipids were determined by a sulfo-phospho-vanillin reaction.  
 
2.2.9   RNA extraction and real-time PCR    
 
Total tissue RNA from adipose tissue, liver, muscle, isolated islets, bone-marrow-derived 
macrophages (BMDMs), and bone-marrow-derived dendritic cells (BMDCs) were isolated according 
to the manufacturer’s instructions (Qiagen, Hombrechtikon, Switzerland). Commercially available 
mouse primers (Applied Biosystems, CA, USA) were used for real-time PCR. For ex vivo detection of 
islet inflammatory genes after HFD feeding, islets were initially allowed to recover for 4 h in 
suspension before extraction of total RNA.  
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2.2.10   Immunohistochemistry    
 
Mouse liver and pancreatic cryosections were incubated with an anti-F4/80 primary antibody (clone 
CI:A3-1, BMA Biomedicals, Switzerland), or isotype control rat IgG2b (AbD Serotec, Düsseldorf, 
Germany) and counterstained with haematoxylin and eosin. F4/80 was visualised using goat anti-rat 
antibody (112-005-167) (Jackson ImmunoResearch, Newmarket, UK) and a donkey anti-goat antibody 
conjugated to HRP (Jackson 705-035-147). Images were captured on an Axioplan 2 imaging system 
(Zeiss, Feldbach, Switzerland) and F4/80 positive area/islet positive area was quantified using Image J 
software. For liver sections, three random fields of view were analysed in two sections per animal 
separated by 200 µm (an average of 3,600 ± 100 cells per animal). For the pancreas, all islets in four 
sections separated by 200 µm were analysed per animal (an average of 47 ± 7 islets per animal).  
 
2.2.11   Pancreatic islet isolation and BMDM/BMDC preparation    
 
Mouse islets were isolated by collagenase digestion, followed by Histopaque gradient centrifugation. 
For in vitro islet experiments, islets were plated on extracellular matrix (Novamed, Jerusalem, Israel). 
Islets were allowed to adhere and spread on the extracellular matrix dishes for 48 h before initiation of 
experiments.  
Bone marrow was isolated from femurs and tibias of female mice and cultured in macrophage medium 
consisting of 50% Dulbecco's Modified Eagle Medium supplemented with 20% horse serum and 30% 
L929 conditioned medium (a source of macrophage colony-stimulating factor). After 7 days, cells 
were plated into 24-well plates (5 × 106 cells/well) for experiments and extraction of RNA. To 
generate BMDCs, bone marrow prepared from femurs and tibias was cultured in non-tissue-culture-
treated Petri dishes with RPMI (Roswell Park Memorial Institute) medium supplemented with 2-
mercaptoethanol (50 µM), 10% FCS and 200 U/ml granulocyte macrophage colony-stimulating factor. 
After 7 days, non-adherent cells were plated into 24-well plates (5 × 106 cells/well) for experiments 
and extraction of RNA. The specificity of the two differentiation protocols to generate BMDMs 
(CD45+F4/80+CD11b+Cd11c−) and BMDCs (CD45+CD11b+CD11c+) was verified by FACS 
analysis. BMDM and BMDC were resuspended in FACS buffer (2% FCS, 10 mmol/l EDTA in PBS) 
and incubated with anti-mouse CD16/32 (Fc-block, BD Biosciences, Heidelberg, Germany) for 5 min, 
then stained with anti-mouse CD45-biotin/SAV-APC/Cy7 (BD Biosciences, Heidelberg, Germany), 
F4/80-FITC (BD Biosciences, Heidelberg, Germany), CD11c-PE (Invitrogen, Basel, Switzerland) and 
CD11b-APC (BD Biosciences, Heidelberg, Germany) for 20 min. The cells were analysed with a 
Partec FloMax flow cytometer (Münster, Germany). 7-AAD (7-amino-actinomycin D, Invitrogen) was 
used to exclude nonviable cells in flow cytometric analysis. Cells were treated for 6 h with BSA or a 
0.5 mmol/l palmitate:oleate (2:1 molar ratio) preparation before RNA extraction.  
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2.2.12   TLR2 antibody treatment 
 
Mice were given a weekly dose of 10 mg/kg bodyweight of OPN301, a monoclonal anti mouse TLR2 
antibody, isotype control antibody or saline, respectively. OPN301 and isotype control were 
manufactured by Opsona Therapeuticals, Ireland. 
 
2.2.13   Western blot analysis    
 
Total protein was prepared from perigonadal adipose tissue and blotted for GLUT4 as previously 
published [111]. 
 
2.2.14   Tissue triacylglycerols and glycogen 
 
 To measure triacylglycerol content in muscles, lipids were extracted from approximately 30 mg of 
tissue by homogenisation in 500 µl of acetone. Homogenates were centrifuged twice for 5 min at full 
speed to remove cell debris. Triacylglycerol concentrations were measured using TRIG kit (Diatools, 
Villmergen, Switzerland) according to the manufacturer’s instructions. To measure glycogen content 
in muscles, glycogen was extracted by digesting approximately 20 mg of tissue in 2 mol/l HCl in 
duplicate. Glycogen was measured using the glucose HK kit (Sigma, St Louis, MO, USA).  
 
2.2.15   NEFA preparation 
 
Oleate or palmitate (Sigma, St Louis, MO, USA) were dissolved at 10 mmol/l concentration in RPMI 
medium containing 11% BSA (NEFA- and endotoxin-free) (Sigma) under an N2 atmosphere. Eleven 
% BSA without NEFA served as a control, and effective NEFA concentrations were determined with a 
commercially available kit (Wako chemicals, Neuss, Germany). Dissolved fatty acids were tested for 
endotoxin contamination using the standard Limulus Ameobodyte Lysate assay (Cambrex, Charles 
City, IA, USA), and found to contain minimal levels in the range of 6–58 pg/ml as described [112]. 
Endotoxin levels were similar between BSA controls and NEFA preparations, and these endotoxin 
levels are unable to activate either pancreatic islets [112] or BMDCs [96].  
 
2.2.16   Statistics    
 
Data are expressed as means ± SEM with the number of individual experiments presented in the figure 
legends. All data were analysed using the nonlinear regression analysis programme PRISM 
(GraphPad, CA, USA), and significance was tested using Student’s t test and analysis of variance 
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(ANOVA) with Dunnett’s or Bonferroni’s post-hoc test for multiple comparison analysis. Significance 
was set at p < 0.05.  
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2.3   Results 
 
2.3.1 Tlr2 tissue expression and regulation by HFD feeding 
 
We initially profiled mouse tissue expression of Tlr2 mRNA (Fig. 1A). These data indicated that Tlr2 
has a broad tissue expression profile, which includes not only organs classically described as being 
heavily populated by immune cells (spleen), but also insulin-sensitive tissues and the pancreatic islet. 
Based on this information, we analysed mRNA expression of Tlr1, -2, -4 and -6 in response to 
20 weeks of HFD feeding in female black 6 mice in perigonadal adipose tissue, skeletal quadriceps 
muscle, liver tissue, pancreatic islets and circulating leucocytes (Fig. 1B). Indeed, HFD feeding 
resulted in increased mRNA expression of some of Tlr1, -2, -4 and -6 in all these tissues.  
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Fig. 1   HFD regulation of tissue Tlr1, -2, -4 and -6 mRNA expression. (A) Relative tissue expression profile of 
mouse Tlr2 mRNA based on gene arrays (n = 3 for all tissues except islet, bone marrow and pituitary, where n = 
4). (B) Female C57BL/6J littermate mice were fed a HFD for 20 weeks starting at 10–12 weeks of age. 
Perigonadal adipose tissue, quadriceps skeletal muscle, liver tissue, isolated pancreatic islets and circulating 
leucocytes were isolated and analysed for Tlr expression by quantitative PCR (chow n = 7, HFD n = 8). White 
bars, Tlr1; red bars, Tlr2; green bars, Tlr6; blue bars, Tlr4. *p<0.05, as tested by Student’s t test compared with 
chow-fed age-matched control (1.0±SEM)  
 
2.3.2 Tlr2 −/− mice are resistant to the adverse effects of HFD feeding    
 
Based on published data [95, 96, 113] and the upregulation of TLR expression by HFD, we reasoned 
that mice lacking Tlr2 (which are unable to signal via TLR1/2, or TLR2/6 heterodimers) might show 
differences in susceptibility to HFD-induced glucose intolerance. Tlr2 −/− mice were confirmed to be 
unresponsive to the synthetic TLR2 ligand, Pam2CSK4, in vivo (Fig. S1). Further, neither female nor 
male Tlr2 −/− mice on a chow diet showed any difference in glucose tolerance or insulin sensitivity at 
10–12 weeks of age when compared with littermate controls (Tlr2 +/+) (Fig. S2A-D). Thereafter, 
female and male Tlr2 +/+ and Tlr2 −/− mice were put on HFD for 20 weeks, until 32 weeks of age. HFD-
induced weight gain was not different between genotypes in both female (Fig. 2A) and male mice 
(Fig. S3A). After 12 weeks of HFD, female Tlr2 −/− mice already showed improved glucose tolerance, 
insulin sensitivity and β-cell insulin secretion in response to a glucose challenge (Fig. S4). At this age 
male Tlr2 −/− mice were also more insulin sensitive compared with Tlr2 +/+ littermates, while showing 
no differences in glucose tolerance or insulin secretion (Fig. S3B-D). After 20 weeks of HFD, female 
Tlr2 −/− mice (aged 32 weeks) showed markedly improved glucose tolerance, insulin sensitivity and β-
cell insulin secretion in response to a glucose challenge (Fig. 2B-D). Supporting improved peripheral 
insulin sensitivity, fasting circulating insulin levels were reduced both at 12 and 20 weeks of HFD 
feeding in female Tlr2 −/− mice compared with Tlr2 +/+ controls (Fig. 2D and Fig. S4C). Age-matched 
32-week-old chow-fed female Tlr2 +/+ and Tlr2 −/− mice showed no differences in glucose homeostasis 
(Fig. S2E-F). Based on these data, we focused on female Tlr2 −/− mice for the remainder of the study. 
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Fig. 2  Tlr2 −/− mice are resistant to the adverse effects of HFD feeding. (A) Female Tlr2 +/+ and Tlr2 −/− 
littermate mice were fed an HFD starting at 10–12 weeks of age, and body weight was monitored (n = 7 for 
chow groups, n = 31 for HFD Tlr2 +/+ and n = 32 for HFD Tlr2 −/−). (B) An IPGTT (2 g/kg glucose) was 
performed after 20 weeks of HFD feeding (32-week-old mice; n = 21 for HFD Tlr2 +/+ and n = 22 for HFD 
Tlr2 −/−). (C) An ITT (0.85 U/kg insulin) was performed after 20 weeks of HFD feeding (32-week-old mice; 
n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). (D) Insulin secretion during an IPGTT performed after 
20 weeks of HFD feeding (32-week-old mice; n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). Black open 
square, chow Tlr2 +/+; red open square, chow Tlr2 −/−; black filled squares and unbroken line, HFD Tlr2 +/+; red 
filled squares and broken line, HFD Tlr2 −/− .*p < 0.05 and **p < 0.01, as tested by Student’s t test compared 
with Tlr2 +/+ control  
 
We went on to investigate insulin target tissue inflammation and insulin sensitivity in addition to 
examining islet inflammation and islet insulin secretion. HFD-fed female Tlr2 −/− mice had reduced 
perigonadal fat pad weight compared with wild-type animals, in addition to having smaller adipocytes 
that displayed improved insulin-stimulated glucose uptake (Fig. 3A-D). This was consistent with 
increased GLUT4 protein levels in whole adipose tissue of Tlr2 −/− mice (Fig. S5). Interestingly, HFD-
induced adipose tissue cytokine mRNA expression was similar between genotypes, with only the 
chemokine Mcp-1, and the macrophage marker Cd68, showing reductions in mRNA in Tlr2 −/− mice 
on HFD (Fig. 3E). Further, mRNA expression of Cd36, the fatty acid translocase known to associate 
with TLR2 [114], was unchanged in adipose tissue (Fig. 3F).  
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Fig. 3   Adipose tissue in female Tlr2 +/+ and Tlr2 −/− mice after 20 weeks of HFD feeding. (A) Perigonadal fat 
pad weight as % body weight in chow- and HFD-fed female Tlr2 +/+ and Tlr2 −/− mice (n = 13 chow Tlr2 +/+, 
n = 15 chow Tlr2 −/−, n = 21 HFD Tlr2 +/+, n = 23 HFD Tlr2 −/−).*p < 0.05 relative to Tlr2 +/+ chow control 
and #p < 0.05 relative to Tlr2 +/+ HFD, as tested by ANOVA with Newman–Keuls post hoc test. (B) Insulin 
(INS)-stimulated glucose incorporation in isolated perigonadal adipocytes (n = 4 per group). (C) Perigonadal 
adipocyte size distribution (n = 4 per group). (D) Representative image of perigonadal adipose tissue. (E) 
Relative cytokine, chemokine and macrophage/dendritic cell marker mRNA expression in perigonadal adipose 
tissue compared with chow-fed Tlr2 +/+ animals (n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). (F) Cd36 
mRNA expression compared with chow-fed Tlr2 +/+ animals (n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 
−/−). Black open bars, chow Tlr2 +/+; red open bars, chow Tlr2 −/−; black filled bars, HFD Tlr2 +/+; red filled bars, 
HFD Tlr2 −/−. All but (A) *p < 0.05 as tested by Student’s t test  
 
In agreement with reduced adiposity, circulating leptin, MCP-1 and TNF-α levels were significantly 
reduced in female Tlr2 −/− animals after 20 weeks of HFD feeding. However, we did not detect 
differences in circulating resistin, IL-6, cholesterol, NEFAs or ketones. In support of improved insulin 
sensitivity, circulating triacylglycerol levels were significantly reduced in Tlr2 −/− mice on HFD 
(Table S1). Given the reduced adiposity of female Tlr2 −/− mice on HFD, we investigated energy 
homeostasis in these animals during HFD feeding. Despite reduced adiposity, Tlr2 −/− mice tended to 
consume more calories (10% more) (Fig. 4A). At the same time, we observed a parallel 10% increase 
in total energy expenditure, an effect that was more pronounced during dark phases (Fig. 4B). 
Increased total energy expenditure was not due to increased physical activity (Fig. 4C). Interestingly, 
Tlr2 −/− mice preferentially used lipids as an energy source as indicated by a significantly reduced 
respiratory quotient (RQ), especially during the light phases (Fig. 4D). This was consistent with 
increased skeletal muscle Acox1 and Mcad mRNA expression (enzymes involved in β-oxidation) in 
Tlr2 −/− mice, while other genes involved in fatty acid uptake (Cd36) and inflammation were 
unchanged (Fig. 4E-F). However, at this time point we did not detect differences in skeletal muscle 
triacylglycerols or glycogen content between genotypes (Fig. S6). In summary, female Tlr2 −/− mice 
show reduced adiposity on HFD compared with Tlr2 +/+ littermates. This was consistent with a reduced 
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RQ, and increased mRNA expression of some genes involved in β-oxidation in skeletal muscle. 
Overall energy intake and expenditure were balanced, possibly explaining why body weight did not 
differ between groups. Finally, adipose tissue and skeletal muscle inflammation due to HFD feeding 
was not strongly impacted by lack of TLR2 signalling.  
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Fig. 4   Indirect calorimetry and muscle in female Tlr2 +/+ and Tlr2 −/− mice after 20 weeks of HFD feeding. (A) 
Food intake monitored over four consecutive days as normalised to body weight (p = 0.24). (B) Energy 
expenditure calculated continuously over 48 h and total summed energy expenditure during dark and light 
phases. Time: 0 h = 18:00 h, and represents lights off; 12 h dark and light phases are separated by vertical lines. 
(C) Physical activity monitored by telemetry continuously over 48 h and averaged during dark and light phases. 
(D) RQ calculated continuously over 48 h and averaged during dark and light phases. n = 6 per group for all 
measurements. *p < 0.05 between genotypes as tested by Student’s t test. (E) Relative mRNA expression of 
genes involved in fatty acid metabolism in quadriceps muscle in female Tlr2 +/+ and Tlr2 −/− mice after 20 weeks 
of HFD feeding (n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). *p < 0.05 between genotypes as tested 
by Student’s t test. (F) Relative cytokine, chemokine and macrophage/dendritic cell marker mRNA expression 
(n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). Black bars, or black squares with line, Tlr2 +/+; red bars, or 
red squares with line, Tlr2 −/−. BW, body weight; ND, not detectable  
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2.3.3 Tlr2 −/− mice are protected from liver insulin resistance, hepatosteatosis and liver inflammation 
on HFD  
 
We performed hyperinsulinaemic–euglycaemic clamps to assess peripheral insulin sensitivity in 
female Tlr2 −/− and Tlr2 +/+ mice after HFD feeding for 20 weeks. In agreement with enhanced whole 
body insulin sensitivity observed during the ITT (Fig. 2C), glucose infusion rates were increased in 
Tlr2 −/− mice concomitant with insulin-stimulated glucose turnover (Fig. 5A-B and Fig. S7). Further, 
liver insulin sensitivity was preserved in Tlr2 −/− mice, as demonstrated by a significant reduction in 
hepatic glucose production during the hyperinsulinaemic clamp (Fig. 5C). Lipid content was reduced 
in livers of Tlr2 −/− mice, suggesting protection against the development of hepatosteatosis under HFD 
(Fig. 5D). Consistent with this, mRNA of the fatty acid translocase, Cd36, was strongly reduced in 
Tlr2 −/− mice, whereas genes involved in β-oxidation (Acox1, Cpt1a), oxidative metabolism (Pgc1α 
[also known as Ppargc1a]) or lipogenesis (Fas) were unchanged relative to controls (Fig. 5E). Indeed, 
Tlr2 −/− mice were protected from HFD-induced liver Il-1β, MCP-1 and Cd68 mRNA expression 
compared with Tlr2 +/+ controls (Fig. 5F). However, other HFD-induced cytokines (IL-6, Tnf-α, IL-10) 
and chemokines (MIP-1α [also known as Clcl3], Kc [also known as Cxcl1]) were unchanged between 
genotypes. Consistent with mRNA data, numbers of liver F4/80+ cells (a macrophage marker) were 
unchanged between genotypes on HFD (13.7 ± 1.1 % in Tlr2 +/+ [n = 8] vs 13.5 ± 1.3 % F4/80+ 
cells/total cells in Tlr2 −/− [n = 7]). Thus, female Tlr2 −/− mice are protected from liver insulin 
resistance, hepatosteatosis and some markers of inflammation on HFD.  
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Fig. 5   Liver in female Tlr2 +/+ and Tlr2 −/− mice after 20 weeks of HFD feeding. Hyperinsulinaemic–
euglycaemic clamps were performed after 20 weeks of HFD feeding in female Tlr2 +/+ and Tlr2 −/− littermates. 
(A) Blood glucose during clamping and glucose infusion rate (n = 4). (B) Insulin-stimulated glucose turnover in 
female Tlr2 +/+ and Tlr2 −/− littermates (n = 4). (C) Suppression of hepatic glucose production (HGP) during 
clamp (n = 4). (D) Representative liver stained with haematoxylin and eosin and total liver lipids (n = 7 for 
HFD Tlr2 +/+ and n = 8 for HFD Tlr2 −/−). (E) Relative mRNA expression of genes involved in fatty acid 
transport (Cd36), β-oxidation (Acox1, Cpt1a, Pgc1α) and lipogenesis (Fas). (F) Relative cytokine, chemokine 
and macrophage/dendritic cell marker mRNA expression in liver isolated from female HFD Tlr2 +/+ and Tlr2 −/− 
littermates compared with chow Tlr2 +/+ controls (n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). Black 
bars, Tlr2 +/+; red bars, Tlr2 −/−. *p < 0.05 and **p < 0.01 as tested by Student’s t test compared with Tlr2 +/+ 
control  
 
2.3.4 Tlr2 −/− mice are protected from impaired β-cell insulin secretion and islet inflammation on 
HFD 
 
We isolated pancreatic islets after 20 weeks of HFD feeding from female littermate Tlr2 +/+ and Tlr2 
−/− mice. Islets from Tlr2 −/− mice responded to an increased glucose concentration by increasing 
insulin secretion while Tlr2 +/+ islets showed no response to glucose (Fig. 6A). There was no 
difference in islet insulin content between genotypes (not shown). There was also no difference in 
glucose-stimulated insulin secretion between age-matched 32-week-old chow-fed Tlr2 +/+ and Tlr2 −/− 
mice (not shown). This supports our in vivo findings (Fig. 2D) that female Tlr2 −/− mice on HFD show 
improved β-cell insulin secretion compared with littermate Tlr2 +/+ controls.  
 
Next, we analysed islet inflammation due to HFD feeding in female Tlr2 +/+ and Tlr2 −/− mice. 
Increases in islet Il-1β mRNA owing to HFD positively correlated with increased 
macrophage/dendritic cell marker expression: Cd68, F4/80 (also known as Emr1) and Cd11c (also 
known as Itgax) (Fig. 6B) (for Cd68 r 2 = 0.91, p = 0.0003; for F4/80 r 2 = 0.92, p = 0.0006; for 
Cd11c r 2 = 0.60, p = 0.02; n = 8). By contrast, islets from Tlr2 −/− mice on HFD were protected 
from increased Il-1β, Cd68 and F4/80 mRNA. Furthermore, Il-6, Tnf-α, Mcp-1 and Kc mRNA was 
also significantly reduced in Tlr2 −/− versus Tlr2 +/+ islets on HFD, with no effect on islet Cd36 
expression (Fig. 6C-D). No reductions in these inflammatory markers were observed in islets isolated 
from sex- and age-matched chow-fed Tlr2 −/− compared with Tlr2 +/+ mice (not shown). In contrast to 
F4/80 mRNA data, and similar to the liver, the amount of islet F4/80+ cells were unchanged in HFD 
Tlr2 −/− mice (percentage area of F4/80+ cells of total islet area: 1.9 ± 0.4% in Tlr2 +/+ [n = 4] versus 
1.8 ± 0.4% in Tlr2 −/− [n = 4]), possibly suggesting an altered activation status of liver and islet 
macrophages/dendritic cells in Tlr2 −/− versus Tlr2 +/+ mice on HFD.  
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Finally, analysis of total peripheral leucocytes did not show differences in cytokine mRNA (Il-1β, Tnf-
α) or macrophage marker expression (Cd68, F4/80) between Tlr2 genotypes on HFD (data not 
shown), supporting the tissue specificity of the inflammatory response.  
 
       
 
 
 
 
 
Fig. 6   Pancreatic islet in female Tlr2 +/+ and Tlr2 −/− mice after 20 weeks of HFD feeding. (A) Pancreatic islets 
were isolated after 20 weeks of HFD feeding in Tlr2 +/+ and Tlr2 −/− littermates and static glucose-stimulated 
insulin secretion was performed using 2.8 mmol/l glucose and 16.7 mmol/l glucose (1 h each, 15 islets/well) and 
normalised for total islet insulin content. Content was unchanged between genotypes (n = 8 for HFD Tlr2 +/+ 
and n = 7 for HFD Tlr2 −/−). *p < 0.05 as tested by Student’s t test. (B) Pancreatic islets isolated from chow- 
and HFD-fed Tlr2 +/+ mice were analysed for Il-1β, Cd68, F4/80 and Cd11c mRNA expression by quantitative 
PCR. There is a strong positive correlation between islet Il-1β mRNA and islet Cd68, F4/80 or Cd11c mRNA 
under HFD conditions (for Cd68 r 2 = 0.91, p = 0.0003, black squares; for F4/80 r 2 = 0.92, p = 0.0006, 
black circles; for Cd11c r 2 = 0.60, p = 0.02, white triangles; n = 8). (C) Relative cytokine, chemokine and 
macrophage marker mRNA expression in pancreatic islets isolated from female HFD-fed Tlr2 +/+ and Tlr2 −/− 
littermates compared with chow Tlr2 +/+ controls (n = 8 for HFD Tlr2 +/+ and n = 7 for HFD Tlr2 −/−). (D) 
Relative islet Cd36 mRNA expression in HFD-fed Tlr2 +/+ and Tlr2 −/− mice (n = 8 for HFD Tlr2 +/+ and n = 7 
for HFD Tlr2 −/−). Black bars, Tlr2 +/+; red bars, Tlr2 −/−. *p < 0.05 as tested by Student’s t test compared with 
Tlr2 +/+ control  
 
   30  
 
 
2.3.5 Impaired inflammatory response of BMDCs and islets to NEFAs in Tlr2 −/− mice    
 
Numbers of F4/80+ cells in the liver and islets were unchanged, despite reductions in Il-1β mRNA in 
these tissues in Tlr2 −/− mice. Thus, we hypothesized that tissue immune cells (macrophages and/or 
dendritic cells) from Tlr2 −/− mice and/or parenchymal tissue itself may display a reduced ability to 
mount an inflammatory response to certain ligands present during HFD feeding. BMDMs and BMDCs 
from Tlr2 +/+ and Tlr2 −/− mice were cultured for 6 h in the presence of endotoxin-free BSA control or 
a mix of 0.5 mM palmitate:oleate (2:1). Indeed, BMDCs from Tlr2 −/− mice displayed an attenuated Il-
1β mRNA response to the NEFAs, whereas BMDMs did not (Fig. 7A-B). Both BMDMs and BMDCs 
from Tlr2 −/− mice were unable to respond to the Tlr2 ligand Pam2CSK4 (Fig. S8). As a representative 
tissue, we also investigated the response of pancreatic islets from Tlr2 +/+ and Tlr2 −/− mice to NEFAs. 
Palmitate (0.1 mmol/l) induced Il-1β mRNA 2.5-fold in Tlr2 +/+ islets, whereas this effect was absent 
in islets from mice lacking Tlr2 (Fig. 7C). This effect was specific for the NEFA palmitate, as oleate 
(18:1) alone was unable to increase islet Il-1β mRNA expression (not shown). The IL-1β-induced Il-
1β auto-amplification system [115] was unchanged in Tlr2 −/− islets vs Tlr2 +/+ controls, indicating no 
developmental defect in Tlr2 −/− islets with respect to the induction of Il-1β mRNA expression 
(Fig. 7D).  
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Fig. 7   Impaired inflammatory response to NEFAs in BMDCs and islets of Tlr2 −/− mice. BMDMs (A) and 
BMDCs (B) were prepared from Tlr2 +/+ and Tlr2 −/− mice as described and treated for 6 h with BSA control or 
palmitate:oleate (16:0:18:1, 2:1 molar ratio, 0.5 mmol/l). RNA was extracted and IL-1β mRNA is shown relative 
to 18S (n = 3 for Tlr2 +/+, n = 4 for Tlr2 −/−). (C) Regulation of islet IL-1β mRNA by 48 h treatment with 
0.1 mmol/l palmitate in Tlr2 +/+ and Tlr2 −/− islets (n = 3–7). (D) Regulation of islet IL-1β mRNA by 48 h 
treatment with 0.2 ng/ml IL-1β in Tlr2 +/+ and Tlr2 −/− islets (n = 3–7). Black open bars, Tlr2 +/+; red open bars, 
Tlr2 −/−.*p < 0.05 as tested by Student’s t test compared with BSA genotype control  
 
2.3.6 Tlr2 deficiency does not protect db/db mice from hyperglycemia  
 
To confirm the beneficial effects of Tlr2 deficiency in obesity associated hyperglycemia, Tlr2 -/- mice 
were cross bred with db/db mice [116]. These mice have non functional leptin receptors and 
subsequently impaired leptin signalling due to a deleterious point mutation in the diabetic (db) gene. 
Hyperphagy that originates from lack of leptin signalling in the hypothalamus leads to increased fat 
deposition, hyperinsulinaemia and hyperglycemia [117]. Db/db Tlr2 −/− mice were confirmed to be 
unresponsive to the synthetic TLR2 ligand, Pam2CSK4, in vivo (not shown). Weight gain was similar 
in  db/db Tlr2 +/+ and db/db Tlr2 −/− mice (Fig. 8A) and also glucose tolerance did not differ, as 
assessed by an IPGTT at 7 weeks of age (Fig. 8B) and 10 weeks of age (not shown). Blood glucose 
values (Fig. 8C) and plasma insulin (Fig. 8D) were not significantly different in db/db Tlr2 +/+ and 
db/db Tlr2 −/− mice, although plasma insulin was markantly increased in the latter. 
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Fig. 8   Tlr2 deficiency does not protect db/db mice from hyperglycemia. (A) Weight gain of  db/db Tlr2 +/+, 
db/db Tlr2 −/− and db/wt Tlr2 +/− mice (n = 4 for db/db Tlr2 +/+, n = 6 for db/db Tlr2 -/-, n = 6 for db/wt Tlr2 +/-
). (B) An IPGTT (0.2 g/kg bodyweight) was performed at 7 weeks of age (n = 4 for db/db Tlr2 +/+, n = 4 for 
db/db Tlr2 -/-). Mice were fasted for for 3h (8:00 - 11:00) and blood glucose (C) and plasma insulin (D) were 
assessed (n = 4 for db/db Tlr2 +/+, n = 6 for db/db Tlr2 -/-, n = 5 for db/wt Tlr2 +/-). White open square or bar, 
db/wt Tlr2 +/-; black square or bar, db/db Tlr2 +/+; red square or bar, db/db Tlr2 −/−. *p < 0.05 as tested by 
ANOVA with Dunnett post-hoc test or by Student’s t test compared with db/db Tlr2 +/+  
 
2.3.7 Treatment with an anti Tlr2 antibody fails to show beneficial effects in mice on a HFD 
 
Finally, we took a pharmacological approach and investigated the potentially beneficial effect of 
OPN301, a monoclonal anti mouse TLR2 antibody in an intervention study. 10 week old C57bl/6 
wildtype mice were put on HFD for 15 weeks and thereafter evenly distributed into treatment groups 
according to bodyweight and fed blood glucose values. Mice were injected weekly with 10 mg/kg 
bodyweight OPN301, 10 mg/kg bodyweight isotype control (IgG) or saline and 10 weeks later 
metabolic parameters were analyzed.  
 
HFD-induced weight gain was not different between treatment groups (Fig. 9A). Mice receiving 
OPN301 tended to have lower fed and fasted blood glucose levels compared to saline injected mice, 
similar to the effects seen in istoype control treated littermates (Fig. 9B-C). While insulin sensitivity 
was not different between groups (Fig. 9D), glucose tolerance tended to be improved in OPN301 
treated animals (Fig. 9E), again to a similar level as the isotype control group. Insulin secretion 
following a glucose challenge was improved in OPN301 mice and even more in isotype controlled 
mice (Fig. 9F). 
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Fig. 8   Tendency towards lower blood glucose and improved insulin secretion in OPN301 and isotype treated 
mice on HFD. (A) Bodyweight of wild type littermate mice that were fed an HFD for 15 weeks prior to weekly 
anti TLR2 antibody, isotype or saline injections (n = 11-13 for chow group, n = 12 for HFD OPN301, isotype 
and saline group). After 10 weeks of treatment, animals were fasted for 3h (B) (n = 6 for chow group, n = 8 
for HFD OPN301, isotype and saline group) or 12h (C) (n = 4 for chow group, n = 4 for HFD saline, n = 8 
for HFD OPN301 and isotype group) and blood glucose was determined. (D) An ITT (1.20 U/kg insulin) was 
performed (n = 6 for chow group, n = 8 for HFD OPN301, isotype and saline group). (E) An IPGTT (2g/kg 
glucose) was performed (n = 4 for chow group, n = 4 for HFD saline, n = 8 for HFD OPN301 and isotype 
group). (F) Insulin secretion during an IPGTT (n = 4 for chow group, n = 4 for HFD saline, n = 8 for HFD 
OPN301 and isotype group). White open circle or bar, chow saline; black square or bar, HFD saline; red triangle 
or bar, HFD OPN301; green triangle or bar, HFD isotype. *p < 0.05 and ***p < 0.001, as tested by ANOVA 
with Dunnett post-hoc test compared with HFD saline  
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2.4   Supplementary Results 
 
2.4.1   Pam2CSK4 does not induce SAA in Tlr2 -/- mice 
 
 
Fig. S1   Pam2CSK4 does not induce SAA in Tlr2 -/- mice. 5 µg Pam2CSK4 or saline was injected 
intraperioneally into Tlr2 +/+ (n = 7-8) and Tlr2 -/- mice (n = 3-7) and plasma serum amyloid A (SAA) was 
analyzed by ELISA after 24 h. Black open bars, Tlr2 +/+; red open bars, Tlr2 −/−. *p<0.05 compared to saline 
control and # p<0.05 compared to +/+ Pam2CSK4 as tested by ANOVA with Newman Keuls post hoc test 
 
2.4.2 Glucose homeostasis in chow fed Tlr2 +/+ and Tlr2 -/- mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female ITT - 12 wk Female IPGTT - 12 wk A B 
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Fig. S2   Glucose homeostasis in chow fed Tlr2 +/+ and Tlr2 -/- mice. (A) IPGTT (2 g/kg glucose) and (B) ITT 
(0.85 U/kg insulin) in female mice at 12 weeks of age (n = 12 for Tlr2 +/+, n = 10 for Tlr2 -/-). (C) IPGTT (2 
g/kg glucose) and (D) ITT (1.0 U/kg insulin) in male mice at 12 weeks of age (n = 6 for Tlr2 +/+, n = 4 for Tlr2 -
/-). (E) IPGTT (2 g/kg glucose) and (F) ITT (0.85 U/kg insulin) in female mice at 32 weeks of age (IPGTT: n = 4 
for Tlr2 +/+, n = 4 for Tlr2 -/-; ITT: n = 10 for Tlr2 +/+, n = 7 for Tlr2 -/-). Black unbroken line, Tlr2 +/+; red 
broken line, Tlr2 −/−. 
 
2.4.3 Glucose homeostasis in male Tlr2 +/+ and Tlr2 -/- mice fed HFD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female IPGTT - 32 wk Female ITT - 32 wk 
E F 
Weight gain 
ITT - 12 wk HFD 
IPGTT - 12 wk HFD 
Insulin in vivo - 12 wk HFD 
A B 
C D 
   36  
 
 
Fig. S3   Glucose homeostasis in male Tlr2 +/+ and Tlr2 -/- mice fed HFD. (A) Male Tlr2 +/+ and Tlr2 -/- 
littermate controls were fed a HFD starting at 10-12 weeks of age and body weight was monitored. (B) IPGTT (2 
g/kg glucose) was performed after 12 weeks of HFD feeding. (C) ITT (1.0 U/kg insulin) was performed after 12 
weeks of HFD feeding. (D) Insulin secretion during an IPGTT performed after 12 weeks of HFD feeding (n = 10 
for Tlr2 +/+, n = 12 for Tlr2 -/- for all data). Black unbroken line, Tlr2 +/+; red broken line, Tlr2 −/−. *p<0.05 as 
tested by Student’s t-test compared to Tlr2 +/+ control 
 
2.4.4 Glucose homeostasis in female Tlr2 +/+ and Tlr2 -/- mice fed HFD for 12 weeks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4. Glucose homeostasis in female Tlr2 +/+ and Tlr2 -/- fed HFD for 12 weeks. (A) An IPGTT (2 g/kg 
glucose) was performed after 12 weeks of HFD feeding (n = 13 for Tlr2 +/+, n = 15 for Tlr2 -/-). (B) An ITT 
(0.85 U/kg insulin) was performed after 12 weeks of HFD feeding (n = 12 for Tlr2 +/+, n = 11 for Tlr2 -/-). (C) 
Insulin secretion during the IPGTT (n = 8 for Tlr2 +/+, n = 7 for Tlr2 -/-). Black unbroken line, Tlr2 +/+; red 
broken line, Tlr2 −/−. *p<0.05 and **p<0.01 as tested by Student’s t-test compared to +/+ control 
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2.4.5 Adipose tissue GLUT4 expression in female Tlr2 +/+ and Tlr2 −/− mice fed HFD for 20 weeks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S5   Adipose tissue GLUT4 expression in female Tlr2 +/+ and Tlr2 −/− mice fed HFD for 20 weeks. Protein 
was extracted from whole perigonadal adipose tissue and analysed using anti-GLUT4 and anti-actin antibodies 
as shown. Four representative samples are shown from each genotype, and quantification was performed on 
n = 9 for Tlr2 +/+ and n = 9 for Tlr2 −/− . Black bars, Tlr2 +/+ ; red bars, Tlr2 −/− . *p < 0.05 as tested by 
Student’s t test compared with Tlr2 +/+ control  
 
2.4.6 Skeletal muscle triacylglycerols and glycogen content in female Tlr2 +/+ and Tlr2 −/− mice fed 
HFD for 20 weeks 
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Fig. S6   Skeletal muscle triacylglycerols and glycogen content in female Tlr2 +/+ and Tlr2 −/− mice fed HFD for 
20 weeks. (A) Skeletal muscle triacylglycerols were quantified as described (n = 9 for Tlr2 +/+ , n = 10 for 
Tlr2 −/− ). (B) Skeletal muscle glycogen content was quantified as described (n = 9 for Tlr2 +/+ , n = 10 for 
Tlr2 −/− ). Black bars, Tlr2 +/+ ; red bars, Tlr2 −/− 
 
2.4.7 Blood glucose and glucose infusion rate during hyperinsulinaemic–euglycaemic clamp 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S7   Blood glucose and glucose infusion rate during hyperinsulinaemic–euglycaemic clamp. 
Hyperinsulinaemic–euglycaemic clamps were performed after 20 weeks of HFD feeding in female Tlr2 +/+ and 
Tlr2 −/− littermates. (A) Blood glucose levels were clamped between 5 and 6 mmol/l in both Tlr2 +/+ and Tlr2 −/− 
mice. (B) To maintain euglycaemia, glucose infusion rate was adjusted over time (n = 4). Black squares, 
unbroken line, Tlr2 +/+; red squares, broken line, Tlr2 −/−  
 
2.4.8 Pam2CSK4-induced Il-1β mRNA in BMDMs and BMDCs derived from Tlr2 +/+ and Tlr2 −/− 
mice 
 
 
 
 
 
 
 
 
 
 
 
Fig S8   Pam2CSK4-induced Il-1β mRNA in BMDMs and BMDCs derived from Tlr2 +/+ and Tlr2 −/− mice. (A) 
BMDMs and (B) BMDCs were prepared from Tlr2 +/+ and Tlr2 −/− mice as described and treated for 6 h with 
A B 
A B 
BMDM BMDC 
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100 ng/ml Pam2CSK4. RNA was extracted and Il-1β mRNA is shown relative to 18S (n = 3 for Tlr2 +/+ , n = 4 
for Tlr2 −/− ). Black open bars, Tlr2 +/+ ; red open bars, Tlr2 −/− . *p < 0.05 compared with control and 
#p < 0.05 compared with Tlr2 +/+ Pam2CSK4 as tested by ANOVA with Newman–Keuls post hoc test 
 
2.4.9 Plasma analysis of age-matched chow and 20-week-old HFD-fed female Tlr2 +/+ and Tlr2 –/– 
mice 
 
 Chow HFD 
 +/+ (n=7) –/– (n=7) +/+ (n=8) –/– (n=7) 
Leptin (pg/ml) 710±174 926±288 4611±978 1700±593* 
Resistin (pg/ml) 1304±142 1528±101 3940±673 2988±438 
Cholesterol 
(mmol/l) 2.1±0.2 2.5±0.5 1.7±0.3 1.50±0.3 
NEFA (mmol/l) 0.84±0.12 0.71±0.03 0.64±0.7 0.7±0.06 
Triacylglycerols 
(mmol/l) 0.88±0.08 0.78±0.11 1.2±0.1 0.96±0.04* 
Ketones 
(mmol/l) 0.26±0.03 0.31±0.03 0.31±0.04 0.26±0.05 
IL-6 (pg/ml) 2.7±0.6 4.7±1.3 3.6±0.4 5.0±0.9 
TNF- (pg/ml) 3.3±0.5 3.5±0.7 4.3±0.4 3.2±0.1* 
MCP-1 (pg/ml) 11.5±1.3 25.8±8.3 22.8±4.2 14.1±0.3* 
 
Table S1 Plasma analysis of age-matched chow and 20-week-old HFD-fed female Tlr2 +/+ and Tlr2 –/– mice.  All 
data are representative of fasting values and littermate mice at 30–32 weeks of age. *p<0.05 compared with Tlr2 
+/+ HFD 
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2.5 Discussion 
According to the World Health Organization (WHO), the global incidence of diabetes in the 
year 2000 was 2.8%, corresponding to 171 million people worldwide [118]. Due to changing 
life habits, urbanisation and aging the global incidence rate is estimated to increase to 4.4% in 
2030, corresponding to 366 million people worldwide [47]. The major risk factor that 
contributes to this diabetic epidemic is obesity. The current (2009) prevalence of obese 
individuals (BMI ≥ 30) in the USA is 27.2 % [119] with some European countries (especially 
Southern and Eastern Europe) catching up fast [120, 121]. The molecular mechanisms by 
which metabolic stress induces islet inflammation and therefore β-cell damage in vitro and in 
vivo remain elusive. This thesis identifies Tlr2 as a major player in inducing the adverse 
effects of  HFD feeding in mice. 
It has been known for a long time that obesity and Type 2 diabetes are associated with chronic 
activation of the innate immune system [122]. The impact of inflammation on insulin 
resistance and β-cell dysfunction has been confirmed clinically in patients with type 2 
diabetes [97] [75]. A clinical trial in which Type 2 diabetic patients received the naturally 
occurring Il-1β antagonist Il-1Ra, showed that β-cell secretory function was enhanced after 
injection of the Il-1β blocker. Nevertheless, the triggering mechanism responsible for 
induction of the inflammatory response in obesity and type 2 diabetes is not known. Recent 
studies have implicated TLR4 and its associated co-receptor, CD14, in HFD- and NEFA-
stimulated tissue inflammation and insulin resistance. Jeffrey Flier’s group has shown that the 
lack of TLR4 protects against fatty acid induced inflammatory signalling in adipose tissue and 
macrophages [90]. This was confirmed by Poggi et al. who in addition showed that Tlr4 −/− 
mice have blunted lipopolysaccharide-induced insulin resistance in differentiated adipocytes 
[107]. Along the same lines, D.M. Tsukumo et al. published a study demonstrating that Tlr4 
−/−  mice (the same as used by Poggi et al.) are partially protected against the development of 
diet-induced obesity [108]. Additional proof of the importance of TLR4 signalling in the 
obesity-inflammation axis came from P.D. Cani et al. who showed that HFD feeding 
increases plasma lipopolysaccharide. Continuously subcutaneous infusion of 
lipopolysaccharide into mice increased glycaemia, insulinaemia, markers of inflammation in 
adipose tissue and liver insulin resistance. Importantly, mutant mice for CD14, TLR4’s 
associated co-receptor, were protected against most of these lipopolysaccharide-induced 
effects [123]. 
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NEFAs, including palmitate and oleate, can not only activate TLR4 but also TLR2. By 
signalling through TLR2, they induce proinflammatory cytokine production in various tissues, 
leading to tissue-specific impairments. Not all dietary fatty acids have the same effect on 
tissue inflammation. Saturated fatty acids activated but (poly)unsaturated fatty acids inhibited 
TLR2 and TLR4 signalling [89, 94], suggesting that inflammatory responses can be 
modulated depending on the kind of TLRs expressed and the type of dietary fatty acid 
present. A study by J.J. Senn identified TLR2 as indispensable for palmitate-induced insulin 
resistance and IL-6 production in muscle cells [95]. Furthermore, TLR2 and TLR4 mediated 
the proinflammatory activation of BMDC and, to a lesser extent, BMDM [96], highlighting 
the importance of resident and infiltrating subpopulations of macrophages for fatty acid 
mediated tissue inflammation. 
Based on these published data and the upregulation of TLR expression by HFD, we decided 
to investigate TLR2 in the context of obesity, insulin resistance and diabetes. Here, we show 
that TLR2 signalling is detrimental for proper glucose homeostasis under HFD conditions. 
Overall, TLR2 deficiency protected from HFD-induced insulin resistance and β-cell 
dysfunction via regulation of energy substrate utilisation and tissue inflammation. 
During the preparation of this thesis, another study on the role of genetic deletion of TLR2 
during HFD feeding was published [106]. Overall, their data on improved whole body glucose 
homeostasis and liver lipid content are consistent with our data. Our study extends on these 
data and indicates that a lack of TLR2 positively regulates energy-substrate utilisation, hepatic 
and adipose tissue insulin sensitivity, β-cell insulin secretion and liver and islet tissue 
inflammation. Furthermore, our in vitro data suggest a role for TLR2 in tissue immune cells 
(BMDCs) or parenchymal tissue itself (islets) in regulating the inflammatory response to 
elevated fatty acids during HFD feeding. 
Our male and female Tlr2 −/− mice were less protected from HFD than the male Tlr2 −/− mice 
used in the study of Himes and Smith [106]. This may be explained by differences in diets 
used, or the use of littermate controls in our study, a critical point not mentioned in the other 
study. Indeed, we initially also performed our experiments on non-littermate-controlled Tlr2 
+/+ and Tlr2 −/− mice, with data matching those of Himes and Smith in male mice (not shown). 
Repeating the study with littermate mice resulted in the sexually dimorphic phenotype shown 
here in response to HFD, and a milder resistance to the obesity phenotype than the one 
published [106]. Interestingly, our data are similar to a published report on Tlr4 −/− mice [90], 
which also showed sexual dimorphism in their resistance to the adverse effects of HFD 
feeding, with males showing only a partial resistance compared to females. Currently we 
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cannot explain these differences, but it will be interesting to investigate the effects of sex on 
tissue inflammation with respect to obesity and diabetes. 
After 20 weeks of HFD, Tlr2 −/− mice showed lower adiposity than their Tlr2 +/+ littermates. 
Therefore, we investigated energy homeostasis in these mice. Surprisingly, the caloric intake 
in Tlr2−/− mice was 10%  higher, despite reduced adiposity. This observation was paralleled 
by a 10% increase in total energy expenditure, which was more pronounced during the night 
when rodents are active. Therefore, we tested if this increased energy expenditure was due to 
altered locomotor behaviour, but we could not detect any change in physical activity. 
Moreover, Tlr2 −/− had a reduced RQ, especially during the light phases, which means that 
they preferentially used lipids as an energy source. This was consistent with increased mRNA 
expression of enzymes involved in β-oxidation of fatty acids in skeletal muscle of Tlr2 −/− 
(Acox1 and Mcad). However, skeletal muscle triacylglycerols and glycogen content between 
genotypes were not different. Perigonadal fat pad weights were reduced in Tlr2 −/− mice. Their 
adipocytes were smaller, displayed improved insulin-stimulated glucose uptake and GLUT4 
protein levels in whole adipose tissue was increased in Tlr2 −/− mice. This overall attenuated 
adiposity, together with a reduction in liver lipid content in Tlr2 −/− animals, suggests that 
fatty acids are being shunted away from the liver to be increasingly oxidised in other tissues, 
such as skeletal muscle. This would be consistent with a diminished capacity of the liver to 
take up lipids due to suppressed Cd36 mRNA expression. TLR2 has been shown to associate 
with CD36 at the plasma membrane following receptor ligand activation, suggesting that the 
absence of TLR2 activation in the liver may protect from fatty acid uptake [114]. 
Reduced adiposity and reduced hepatosteatosis were also consistent with overall 
improvements in whole body and hepatic insulin sensitivity as determined by the 
hyperinsulinaemic–euglycaemic clamp. Thus, our data show for the first time that TLR2 
regulates hepatic insulin sensitivity during HFD, extending findings that reduced TLR2 
expression by antisense oligonucleotides improved insulin signalling in muscle and white 
adipose tissue of HFD-fed mice [109]. 
Beyond improved insulin sensitivity, we also observed improvements in β-cell insulin 
secretion in response to glucose load, both in vivo and in vitro. 20 weeks of HFD feeding 
abolished glucose stimulated insulin secretion in isolated islets of Tlr2 +/+ mice. In contrast, 
isolated islets from littermate Tlr2 −/− mice were able to secrete insulin in response to 
increased glucose concentrations. Since there was no difference in islet insulin content 
between genotypes, it can be ruled out that a developmental defect resulting in reduced insulin 
synthesis is responsible for the described differences, although a developmental defect in the 
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insulin secretion pathway cannot be excluded. In accordance with these ex vivo findings, 
compared with HFD-fed Tlr2 +/+ mice, littermate Tlr2 −/− mice showed markedly improved 
glucose tolerance and β-cell insulin secretion in response to a glucose challenge in vivo. 
Furthermore, Tlr2 −/− mice were more sensitive to insulin and had reduced fasting circulating 
insulin levels, as tested by insulin injection and subsequent blood glucose sampling. Thus, the 
overall improved glucose tolerance of HFD Tlr2 −/− mice was due to improved insulin 
sensitivity and β-cell insulin secretion, which correlated well with a partially attenuated tissue 
inflammatory response in the liver and islet. 
We went on to investigate why tissue inflammation might be suppressed in Tlr2 −/− mice on 
HFD. Reductions in tissue inflammation may be due to reduced immune cell content of 
tissues, a reduced activation status of tissue immune cells or reduced inflammation of the 
parenchymal tissue. Despite reductions in Cd68, and/or F4/80 mRNA levels in adipose tissue, 
liver and in islets, we did not observe differences between genotypes in the number of F4/80+ 
cells by immunohistochemistry in the liver or islet. Thus, we hypothesised that the activation 
status of proinflammatory immune cells in Tlr2 −/− mice or the parenchymal tissue itself had a 
reduced capacity to mount an inflammatory response under HFD conditions. Pro-
inflammatory CD11c+ cells have been causally linked to tissue inflammation and the 
induction of insulin resistance in response to HFD in the C57bl/6 mouse [103]. Our data 
showing increased Cd11c mRNA expression during HFD feeding in adipose tissue, liver 
tissue and islets are consistent with the notion that CD11c+ cells are recruited to these tissues 
during obesity [96, 124]. Indeed, Tlr2 −/− BMDCs (CD45+CD11b+Cd11c+) showed a 
refractory response to NEFA-induced Il-1β mRNA in vitro, whereas BMDMs 
(CD45+F4/80+CD11b+Cd11c−) did not. The pancreatic islet was also tested as a 
representative tissue with respect to NEFA induction of Il-1β mRNA. Consistent with the 
effects seen in BMDCs and our in vivo effects, Tlr2 −/− islets were also refractory to palmitate-
induced IL-1β mRNA. We previously found no effect of oleate on mouse islet Il-1β mRNA 
(not shown) [112]. These data suggest that Tlr2 −/− CD11c+ cells are resistant to the effects of 
NEFAs present in HFD, possibly resulting in the reduced tissue inflammation seen in the liver 
and islets of HFD Tlr2 −/− mice. However, given the broad tissue expression of Tlr2 mRNA, 
we cannot conclude whether the observed reductions in tissue inflammation in vivo are due to 
an immune cell, or parenchymal cell, origin. 
HFD diet-induced obesity only leads to mild hyperglycaemia and diabetes in animal models 
of type 2 diabetes [125]. To examine if similar findings can be obtained in an animal model of 
type 2 diabetes with a stronger diabetes phenotype, we investigated  db/db mice crossed with 
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Tlr2 −/− mice [116]. Since these mice show a massive weight gain in a short period of time we 
expected that the beneficial effect of the absence of TLR2 seen in the HFD model would be 
even more pronounced. To our surprise neither female nor male (not shown) db/db Tlr2 −/− 
were protected from the deleterious effects of obesity compared to their db/db Tlr2 +/+  
littermates. The ability to handle a glucose challenge and also insulin sensitivity were not 
different between genotypes. Female db/db Tlr2 −/− tended to have increased fasted plasma 
insulin levels, suggesting that they might be even more insulin resistant than their wildtype 
littermates. These experiments suggest that the lack of TLR2 has only a minor effect on the 
db/db mouse model. Obese humans have higher leptin levels than lean individuals, but they 
are also leptin resistant [126].  Leptin replacement therapy restored metabolic functions, 
development and immune repertoire in congenital leptin deficient humans (homozygous 
leptin gene mutation as consequence of consanguineous marriage) [127, 128], but 
administration of leptin as a weight-losing drug in obese individuals showed to be only mildly 
effective [129]. Therefore, the db/db mouse is probably not the ideal model for obese humans 
while the HFD model is a more valid representation.  
To examine the pharmacological potential of the inhibition of TLR signalling, we used an 
anti-TLR2 antibody in a HFD intervention study. The TLR2 antibody tended to lower fed and 
fasted blood glucose values without affecting insulin sensitivity and glucose tolerance. In 
response to a glucose challenge, TLR2 antibody treated animals tended to be able to release 
more insulin, an effect which was even more pronounced in isotype treated control mice. In 
general, the isotype control antibody preparation had a similar or even better blood glucose 
improving effect during fasting and after a glucose challenge than the TLR2 specific 
antibody. Therefore, we are not able to conclude that the protective effects seen in Tlr2 −/− 
mice can be reproduced via pharmacological means. This highlights the importance of 
including isotopye control conditions in antibody treatment experiments. Prevention studies 
usually lead to higher statistical significance than intervention studies. This might be 
explained be the fact that it is in general easier to protect something from destruction than 
rebuilding it after demolition. Our congenital Tlr2 −/− model resembles the prevention study 
setup which also hints at using this setup in the initial experiment instead of an intervention 
study setup. Possibly, the lack of effect of the TLR2 antibody is due indirect effects of free 
fatty acids. Indeed, TLR2 activation by free fatty acids may occur independently of ligand 
binding to TRL2. 
Recent data also suggest a role for TLR2 in human type 2 diabetes. One study has shown 
increased production of TLR2 protein in circulating monocytes following feeding of a high-
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fat / high-carbohydrate single meal in healthy lean human participants [130]. Evidence for 
increased TLR2 protein levels in monocytes and increased circulating TLR2 ligands in 
recently diagnosed type 2 diabetes patients has also been reported [131]. Monocytes from 
these type 2 diabetic individuals showed increased proinflammatory cytokine secretion 
following TLR2 stimulation. Further, analysis of adipose tissue from individuals with obesity 
and type 2 diabetes revealed  increased protein levels of TLR2 compared to healthy 
individuals [132]. Whether TLR2 activation also contributes to insulin resistance and β-cell 
dysfunction in humans with type 2 diabetes awaits further investigation. 
In summary, these data show that deficiency in TLR2-mediated signalling has a positive 
impact on glucose homeostasis, insulin sensitivity, insulin secretion and energy-substrate 
utilisation during HFD feeding. The overall improved metabolic phenotype of Tlr2 −/− mice 
on HFD is likely to be due to both reduced fat accumulation and reduced tissue inflammation, 
impacting on tissue-specific functions to improve both insulin sensitivity and secretion. It 
remains to be elucidated, how TLR2 activation occurs during HFD.  
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3    SIRT1 ACTIVATION VIA SRTs DOES NOT DELAY THE ONSET 
OF TYPE 1 DIABETES 
 
3.1   Introduction  
 
3.1.1   Sirtuins 
 
The sir family was originally discovered as gene silencing factors in yeast [133] and it was only 16 
years later when they were shown to be key regulators of lifespan [134, 135]. Especially homologues 
of one family member, the sirtuins (sir2), received a lot of attention because they were implicated in 
promoting the life-prolonging effects of caloric restriction in several species [136]. In yeast and flies, 
sirtuin levels rise during caloric-restriction and overexpression of sir2 extends lifespan [135, 137]. In 
addition, the longevity effect of caloric restriction is absent in sirtuin-deficient yeast and mice [138]. 
This raised the idea that sir2 activation could mimic a low caloric state resulting in improved fat 
utilization and eventually expansion of  lifespan in higher organisms. 
 
3.1.2   SIRT1 
 
SIRT1, one of the 7 known human homologues of the yeast sir2 gene, is a NAD+ dependent protein 
and histone deacetylase that is found both in the nucleus and in the cytoplasm. SIRT1 was shown to be 
involved in genomic stability, DNA repair and stress handling [139]. Sirtuins are also engaged in 
metabolic regulation. PGC-1α mediated gluconeogenesis and fatty acid oxidation in the liver was 
shown to be SIRT1 dependent [140]. SIRT1 also modulates the threshold for cell death. It does so by 
attenuating heat shock proteins [141], by regulating the tumor suppressor protein p53 and by binding 
and deacetylating FOXO3 [142] and thereby inducing stress resistance genes and promoting cell 
survival. Finally, SIRT1 was also shown to be able to deacetylate components of the circadian clock, 
probably linking food availability and sleep/wake rhythms [143]. 
 
3.1.3   SIRT1, metabolic diseases and diabetes 
 
There are several lines of evidence implicating SIRT1 in the development of metabolic diseases and 
thus diabetes. First, SIRT1 modulates glucose homeostasis and insulin secretion, shown by β-cell 
specific SIRT1 overexpressing mice that have improved [144], and SIRT1 deficient mice that have 
deteriorated insulin secretion [145]. The improvement in insulin secretion is believed to be due to 
repressing uncoupling protein 2 [144, 145]. Pharmacological activation [146] or genetic 
overexpression [147, 148] of SIRT1 improves glucose tolerance and protects mice against the 
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deleterious effects of HFD feeding. Blocking SIRT1 genetically or pharmacologically was shown to 
induce insulin resistance, in vitro and in vivo [149].  SIRT1 activity is also advantageous in other age 
related diseases, such as cardiovascular diseases [150, 151], atherosclerosis [152], cancer [153], and 
neurodegeneration in a mouse model of Alzheimer’s disease [154], as well as in cholesterol transport 
[155]. 
A role for SIRT1 in autoimmunity and therefore a possible involvement in the development of type 1 
diabetes emerged recently, when SIRT1 was implicated in T cell tolerance. Self-reactive T cells that 
escape negative selection in the thymus are inactivated in the periphery by clonal anergy which results 
in longterm unresponsiveness to foreign and self antigens. SIRT1 is abundantly expressed in the 
thymus and was shown to suppress activator protein 1 (AP-1) transcriptional activity in T cells [156], 
an important mechanism in T cell anergy [157]. Further, resveratrol, which is believed to activate 
SIRT1, was shown to suppress proliferation and cytokine production in T cells [158]. Thymocytes 
from Sirt1 -/- mice display increased sensitivity to radiation-induced apoptosis [159]. These 
observations suggest that SIRT1 is an important modulator of immunity, acting on T cell development 
and tolerance.  
A hallmark of diabetes is cytokine-induced impairment and destruction of pancreatic β-cells. Among 
TNF and IFN, IL-1β is a major contributor and signals via the NFκB pathway. NFκB acetylation of 
the subunit p65 of NFκB at Lys310 is required for full transcriptional activity. SIRT1 inhibits NFκB 
activity by deacetylating Lys310 and thereby attenuates inflammation [160]. This is also true for the β-
cells, where overexpression of SIRT1 or activation by resveratrol reduced cytokine-mediated 
cytotoxicity via suppression of NFκB activity [161]. 
 
3.1.4   SIRT1 L107P 
 
A novel form of monogenic diabetes with features of both type 1 diabetes (auto-immunity), and type 2 
diabetes (insulin resistance) was found in a family of Ashkenazy Jews. The pattern of inheritance 
amongst the affected family members was indicative of an autosomal dominant mutation. A candidate 
gene approach was used to identify mutations which could explain a combined dysfunction in insulin 
secretion due to a defect in metabolism-secretion coupling, and insulin resistance. In fact, direct 
sequencing of the SIRT1 gene of patients revealed the presence of a T to C exchange in exon 1, 
leading to a leucine107 to proline (L107P) exchange in the SIRT1 protein. Every family member 
diagnosed with type 1 diabetes carried one mutated allele (heterozygous) and non-affected family 
members were healthy, except for two individuals displaying features typical of type 2 diabetes. One 
exception was an 18 year old woman carrying the mutation who displayed severe ulcerative colitis, a 
disease with a profound autoimmune component, a feature shared with type 1 diabetes (Anna Biason-
Lauber et al., manuscript submitted).  
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3.1.5   Small activators of SIRT1 
 
In 2007, novel small-molecule activators of SIRT1 (SRTs) were described [162]. They were found by 
high-throughput mass spectrometry screenings. SRTs seem to bind the enzyme-substrate complex and 
thereby lower the Michaelis constant (KM), which is a measurement for the enzyme-substrate affinity 
[163]. Hence, SRTs increase SIRT1 activity by increasing the binding affinity for acetylated 
substrates. 
The therapeutical potential of SRTs was investigated in several animal models of type 2 diabetes. In 
diet-induced obese and ob/ob mice, SRT1720 and SRT501 improved insulin sensitivity, normalized 
glucose and insulin levels, and elevated mitochondrial capacity [162]. In a metabolic study, SRT1720 
administration enhanced endurance running and protected against diet-induced obesity [146]. This was 
mainly due to promoting fat consumption in skeletal muscle, liver and brown adipose tissue. In 
another animal species, the Zucker fa/fa rat, SRT1720 ameliorated the metabolic disturbances as 
assessed by IPGTT and clamp studies [162]. 
 
3.1.6   Aim of the thesis, SIRT1 part 
 
Several in vivo SIRT1 studies were conducted in the context of type 2 diabetes [144-155], all showing 
that overexpression or activation of SIRT1 increases insulin sensitivity and secretion and ameliorates 
glucose metabolism. Although these studies point to a promising role of SIRT1 as a therapeutic target 
in age-associated diseases and type 2 diabetes, no research on SIRT1 activation in animal models of 
type 1 diabetes was done yet. The detection of a SIRT1 gene mutation in type 1 diabetic patients (see 
above) and reports on the involvement of SIRT1 in autoimmunity [156, 158, 159] lead to the 
following hypothesis. 
 
Hypothesis 1:  Administration of SIRT1 activators (SRTs) delays the onset of diabetes in 
animal models of type 1 diabetes, namely the NOD and the MLD-STZ mouse.  
Hypothesis 2: Genetic ablation of SIRT1 will accelerate the development of MLD-STZ-
induced diabetes.  
Hypothesis 3: The SRT compounds are safe enough to initiate a program to treat the affected 
family members.  
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3.2   Methodology 
 
3.2.1   Animals 
 
NOD (NOD/Ltj) breeding pairs were bought from Charles River Italy. NOD-SCID (NOD.CB17-
Prkdc<scid>/J) breeding pairs were bought from Charles River France. SIRT1+/- (129Sv-
SirT1<tm1Mmc>) mice were a gift from Dr. Michael McBurney (OHRI, Ottawa, Canada). Bl6 
(C57BL/6J) were bred in house. Experimental animals were born and bred in our SPF barrier facility. 
All experiments were done in a littermate controlled fashion. NOD experiments were done with 
females, MLD-STZ experiments with males and adoptive transfer experiments with both genders. 
Experiments were performed according to Swiss veterinary law and institutional guidelines.  
 
3.2.2   SIRT1 activators (SRTs) 
 
Compounds were synthesized at Sirtris Pharmaceuticals, MA, USA. All of them are SIRT1 activators 
with different potencies and specificities [162]. The following dosages were used: 1. STRT 1720 (100 
mg/kg BW), 2. SRT 2379 (100 mg/kg BW), 3. SRT 2104 (200 mg/kg BW), 4. SRT 501 (1000 mg/kg 
BW). They were freshly dissolved in 20% PEG400, 0.5% Tween80 and 79.5% deionized water every 
3 days and applied by oral gavage. The control group received the solvent alone. 
 
3.2.3   NOD experiments 
 
3 week old animals were SRT dosed daily by oral gavage. Drug administration was stopped after 8 
weeks. For insulitis score experiments, 8 animals per group were sacrificed at 12 weeks of age. The 
same animals were used as donors for the adoptive transfer experiments. 20 animals per group were 
tested for glucosuria (Diabur-Test 5000, Roche Diagnostics, Mannheim, Germany) 3 times per week 
(Monday, Wednesday, Friday), starting at 10 weeks of age. Animals positively tested for glucosuria 
were tested for hyperglycaemia (FreeStyle, Abbott, Oxon, UK). Diabetes was defined as random 
blood glucose higher than 14 mM measured on two consecutive days. 
 
3.2.4   MLD-STZ experiments 
 
11 week old animals were distributed into groups of 11-12 animals and i.p. injected with 50 mg / kg 
bodyweight streptozotocin (Sigma, St Louis, MO, USA) or sodium citrate buffer on 5 consecutive 
days. Streptozotocin was prepared freshly by dissolving it in sodium acetate buffer adjusted to pH 4.5. 
In parallel to the first streptozotocin injection, animals were drug dosed with 100 mg/kg bodyweight 
SRT 1720 or solvent daily, according to the following scheme: 
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 - + 
- group 1 group 2 
+ group 3 group 4 
 
Fed blood glucose was measured 3 times per week (Monday, Wednesday, Friday), starting at the day 
of the first STZ injection (FreeStyle, Abbott, Oxon, UK).  
 
3.2.5   Tissue workup 
 
Animals were euthanized by CO2. Blood plasma was harvested by cardiac puncture. Pieces of liver, 
quadriceps muscle and epididimal fat were snap frozen and stored for protein analysis or incubated in 
RNAlater (Ambion / Applied Biosystems, Foster City, CA, USA) over night and snap frozen after 
RNAlater removal and stored for RNA analysis the following day. Pancreata were embedded in 
paraffin and 2 sections 200 µm apart were stained with haematoxylin and eosin. 8 animals and 300-
400 islets per treatment group were scored blindly according to the following: 1. no visible infiltration, 
2. periinsulitis, 3. Insulitis ≤ 50 % infiltation, 4. Insulitis ≥ 50 % infiltration.  
 
3.2.6   Adoptive Transfer 
 
Whole spleens were crushed through a 40 µm cell strainer (BD Falcon, Franklin Lakes, NJ, USA). 
Red blood cells were lysed with ACK (155 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA). Splenocytes 
were resuspended in PBS and injected intra venously into the tail vein of 5 week old female and male 
SCID mice.  
SRT1720 
 STZ 
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3.2.7   Statistics 
 
Data were expressed as means ± S.E.M. All data were analyzed using the nonlinear regression analysis 
program PRISM (GraphPad, CA, USA), and significance was tested using analysis of variance 
(ANOVA) with Bonferronni’s post hoc test or Log-rank (Mantel-Cox) test for survival curves. 
Significance was set at p<0.05. 
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3.3   Results 
 
3.3.1   Diabetes incidence rate  
 
The first experiment was designed to investigate a potential delay in onset of diabetes in NOD animals 
receiving SIRT1 activators (SRTs). Animals were distributed into 4 treatment and 1 control group 
upon weaning in a littermate controlled fashion. Baseline bodyweight and plasma blood glucose 
concentrations were identical in all 5 experimental groups (Fig. 1A-B). Bodyweight development 
during the experimental period was also similar (Fig. 1C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1   Baseline measurements diabetes incidence experiment. Bodyweight (A) and glucose (B) of female NOD 
mice at 3 weeks of age. (C) Bodyweight development during 27 weeks of the experimental phase. n = 20 per 
group. Black bar or line, control; green bar or line, SRT 2379; red bar or line SRT 1720; orange bar or line, SRT 
2104, blue bar or line SRT 501. *p<0.05, as tested by ANOVA with Bonferronni’s post hoc test 
 
Starting at 3 weeks of age animals were SRT dosed daily by oral gavage at a dose of 100 – 1000 
mg/kg body weight. Drug administration was stopped after 8 weeks. Starting at 10 weeks of age 
animals were tested for glucosuria and hyperglycemia 3 times per week. The development of diabetes 
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in the 5 different groups was identical (Fig. 2), indicating that none of the SIRT1 activators is able to 
delay the onset of diabetes in the NOD mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2   Diabetes incidence rate. (A) Diabetes incidence rate of all treatment groups. For illustration purposes 
each group is also plotted against the control group, namely SRT 2379 (B), SRT 1720 (C), SRT 2104 (D), and 
SRT 501 (E). Experiment started with n = 20 per group. Black line, control; green line, SRT 2379; red line SRT 
1720; orange line, SRT 2104, blue line SRT 501. *p<0.05, as tested by Log-rank (Mantel-Cox) test for survival 
curves. 
 
3.3.2   Insulitis score 
 
The second experiment was designed to investigate a potential decrease in immune cell infiltration 
into the pancreas in SRT treated NOD animals. Mice were distributed into 4 treatment and 1 control 
group upon weaning in a littermate controlled fashion. Baseline bodyweight (Fig. 3A) and plasma 
blood glucose concentrations (Fig. 3C) did not differ between experimental groups. Bodyweight and 
plasma blood glucose concentrations were followed during the 8 weeks of SRT administration (Fig. 
3B+D). None of the treatment groups displayed an altered blood glucose or bodyweight development, 
compared to the control group. 
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Fig. 3   Bodyweight and blood glucose concentrations in the insulitis score experimental groups. Bodyweight at 
3 weeks of age (A) and during the 8 weeks of the experimental phase (B). Blood glucose at 3 week of age (C) 
and during the 8 weeks of the experimental phase (D). n = 10 per group. Black bar or line, control; green bar or 
line, SRT 2379; red bar or line SRT 1720; orange bar or line, SRT 2104, blue bar or line SRT 501. *p<0.05, as 
tested by ANOVA with Bonferronni’s post hoc test 
 
Starting at 3 weeks of age animals were SRT dosed daily by oral gavage. Drug administration was 
stopped after 8 weeks. Animals were sacrificed at 12 weeks of age and pancreata were excised and 
analyzed for immune cell infiltration (Fig. 4). SRT treatment did not have a favourable effect  on any 
experimental group. Periinsulitis (less than half of the area covered with infiltrates) was the only 
condition showing significant differences. In contrast to what was expected, SRT 2379 and SRT 501 
treated animals had a higher immune cell infiltration than the control mice, while SRT 1720 and SRT 
2104 treated animals did not show altered immune cell infiltration (Fig. 4B).  
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Fig. 4   Pancreatic immune cell infiltration. (A) Insulitis score. 300-400 islets per treatment group were scored 
blindly according to the following: 1. no visible infiltration (white bar), 2. periinsulitis (gray bar), 3. Insulitis ≤ 
50 % (dark gray bar), 4. Insulitis ≥ 50 % (black bar). (B) Periinsulitis scores of all groups. All other scores did 
not show any significant difference relative to control group. n = 8 per group. Black bar, control; green bar, SRT 
2379; red bar SRT 1720; orange bar, SRT 2104, blue bar SRT 501. *p<0.05, as tested by ANOVA with 
Bonferronni’s post hoc test 
 
3.3.3   Adoptive Transfer of Diabetes 
 
The third experiment was designed to investigate the involvement of regulatory T cells (Treg) in the 
potentially beneficial effects of SIRT1 activation. Therefore, 3 week old female NOD mice were drug 
dosed daily for 8 weeks with activators of SIRT1 (the same animals as described under 3.3.2). At 12 
weeks of age animals were sacrificed, splenocytes were purified and transferred into NOD-SCID 
recipient mice. The next day diabetes was induced by transferring splenocytes from diabetic NOD 
mice into the same NOD-SCID recipient mice. Progression to diabetes was checked thereafter. All of 
the adoptively transferred mice became diabetic, demonstrating that the method worked well. The 
diabetes incidence rate was similar in all groups, suggesting that treatment with the putative SIRT1 
activators via did not influence Tregs (Fig. 5). 
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Fig. 5   Diabetes incidence rate (DIR) in NOD-SCID mice after adoptive transfer (AT) of diabetes. Since not 
enough NOD-SCID recipient mice of one gender were available, experiments were done with male and female 
mice. (A) DIR after AT in female and male recipient mice receiving splenocites from co, SRT 2379, SRT 2104 
and SRT 501 treated animals. This figure is a combination of (C) and (D). (B) DIR of male recipient mice 
receiving splenocites from co and SRT 1720 treated mice. (C) DIR of male recipient mice receiving splenocites 
from co, SRT 2379, SRT 2104 and SRT 501 treated animals. (D) DIR of female recipient mice receiving 
splenocites from co, SRT 2379, SRT 2104 and SRT 501 treated animals. Black lines, control; green lines, SRT 
2379; red lines SRT 1720; orange lines, SRT 2104, blue lines SRT 501. None of the DIR curves were found to 
be significantly different from the co group 
 
3.3.4   Unexpected accumulation of cases of death in SRT1720 and SRT501 treated animals  
 
SRT 1720 and SRT 501 treated animals of experiment 1 (see 3.3.1) showed an accumulation of cases 
of death. These cases occurred mainly during the first 3 weeks of the SRT application (SRT 1720), or 
during the whole period of SRT application (SRT 501) (Fig. 6). 
 
Three SRT1720 treated and two SRT 501 treated animals that died were analyzed by the institute of 
lab animal sciences of University Zürich. Neither a pathological autopsy nor a bacteriological or 
histological analysis revealed any obvious cause of death. Asphyxiation due to perilous gavage 
handling was also ruled out by the autopsy. 
A B 
C D 
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Fig. 6   Cases of death in SRT treated NOD mice. (A) Percentage of total animals that were found dead. (B) 
Number of dead animals per week after start of SRT application (3 weeks of age) in SRT 1720 and SRT 501 
treatment groups. Black bars, control; green bars, SRT 2379; red bars SRT 1720; orange bars, SRT 2104, blue 
bars SRT 501 
 
3.3.5   MLD-STZ-SRT 1720  
 
Since there was no report of toxicity of the SRTs in any other animal model and Sirtris 
Pharmaceuticals never saw side effects in toxicity tests, we concluded that this intolerance could be a 
specific feature of the NOD mouse. After all these mice are immune-compromised and might behave 
different than the standard bl/6 mouse. We therefore established another model of type 1 diabetes, the 
multiple low doses of streptozotocin (MLD-STZ) mouse model. In a pilot study the optimal STZ dose 
was found to be 50 mg/kg bodyweight (Fig. 7A).  Thereafter, littermate bl/6 mice were distributed into 
4 groups with matched bodyweight and blood glucose concentrations. All groups received injections 
of either saline or 50 mg/kg bodyweight STZ on five consecutive days and a daily oral gavage of 100 
mg/kg bodyweight SRT 1720 or solvent, starting at 11 weeks of age. Bodyweight and blood glucose 
were monitored regularly (Fig. 7B+C). SRT 1720 treated animals displayed lower blood glucose 
concentrations in the basal state, but only showed a trend towards improved glycaemia when 
challenged with STZ (Fig. 7C). 
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Fig. 7   MLD-STZ-SRT1720 study. (A) Blood glucose development in a pilot study with 5 injections of 3 doses 
of STZ. n = 4 per group. Black line, control; red line, 40 mg/kg STZ; green line, 50 mg/kg STZ; blue line, 60 
mg/kg STZ. (B) Bodyweight and (C) blood glucose concentrations of STZ and/or SRT 1720 treated mice. 
Broken black line, co mice, n = 11; broken red line, SRT 1720 treated mice, n = 11; solid black line, STZ treated 
mice, n = 12; solid red line, STZ + SRT 1720 treated mice, n = 12. ϒp < 0.05 and ϒϒp < 0.01, as tested by 
Student’s t test compared with control 
 
 
3.3.6   MLD-STZ-SIRT1 +/-  
 
We went on to investigate if genetic ablation of SIRT1 impairs glycaemia. Homozygous SIRT1 
knockout mice are not viable and therefore we treated 11 week old male Sirt1+/- mice with STZ and 
investigated the resulting blood glucose concentrations in comparison to their wildtype littermates. 
0 5 10 15 20 25 30 35 40
0
10
20
30
co
40 mg/kg
50 mg/kg
60 mg/kg
time (days)
B
lo
od
 g
lu
co
se
 (m
M
)
0 5 10 15 20 25 30
22
24
26
28
30
32
time (days)
B
od
yw
ei
gh
t (
g)
A B 
C 
   59  
 
 
Identical to the SRT experiments described above, we injected 5 times 50 mg/kg bodyweight of 
streptozotozin. Unlike in the before described experiment, the destruction of the pancreatic β-cells was 
not severe enough to induce hyperglycemia in these mice. Therefore we injected 3 more doses of STZ 
at days 32-34. There was no overt deterioration due to the lack of one allele of Sirt1.  
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Fig. 8   MLD-STZ-SIRT1. Sirt1 +/- mice and littermate Sirt1 +/+ were injected with 50 mg/kg STZ (days: 1-5 and 
32-34) and random blood glucose concentrations were measured by tail tip bleeding. Broken black line, Sirt1 +/+, 
n = 1; broken blue line, Sirt1 +/-; n = 1; solid black line, Sirt1 +/+, STZ treated, n = 6; solid blue line, Sirt1+/-, STZ 
treated, n = 5. 
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3.4   Discussion 
 
SIRT1, the best studied member of the sirtuin family, is a NAD+ dependent protein and histone 
deacetylase that has pleiotropic functions, ranging from supporting genomic stability, DNA repair and 
stress handling to metabolic regulation [139, 140] and even influencing the circadian clock, linking 
food availability and sleep/wake rhythms [143]. In animal models, SIRT1 also modulates glucose 
homeostasis and insulin secretion and protects from the development of diabetes. It does so by 
increasing insulin secretion (probably via repressing uncoupling protein 2) [144] [145] and by 
improving glucose tolerance as shown in several genetic in vitro and in vivo studies [147, 148] [149]  
as well as pharmacological SIRT1 activation experiments in mice [146].  
Our interest in SIRT1 evolved from a family that carries a SIRT1 point mutation (T to C exchange at   
position 373 of exon 1) leading to a leucine to proline mutation in the SIRT1 protein (L107P). Non-
affected family members were healthy, but the 5 carriers displayed auto-immune diseases. 4 were 
diagnosed with type 1 diabetes and 1 had ulcerative colitis. The index patient was diagnosed with the 
typical features of type 1 diabetes, including a lean body mass, auto-antibodies to islet antigens and a 
rapid dependence on insulin. Strikingly, the patient was also insulin resistant, which is not a typical 
property of type 1 diabetes, even though insulin resistance might be underestimated in patients of type 
1 diabetes [164]. 
SIRT1 animal models support the features described in affected family members. β-cells of 
homozygous SIRT1 knockout mice fail to increase ATP levels after glucose stimulation and display 
reduced insulin secretion [145]. In contrast, targeted over-expression of SIRT1 in β-cells enhances 
insulin secretion [144] and SIRT1 activation by resveratrol enhances insulin sensitivity in vitro and 
protects against HFD-induced insulin resistance [149]. In line with the observed development of type 
1 diabetes in the described family members, homozygous SIRT1-null mice also develop auto-immune 
conditions and produce antibodies that react with nuclear antigens [165]. Furthermore, SIRT1 
deficient mice are predisposed to develop colitis (personal communication, Dr. Lenny Guarente, MIT, 
Cambridge, MA), a disease that one of the carriers of the L107P mutation developed. These findings 
suggest that the phenotype of affected family members could be a consequence of decreased SIRT1 
activity.   
To establish an animal model for the SIRT1 mutation in the patient family, we investigated Sirt1 
knockout mice [166]. As the L107P patients carry the mutation in only one allele, we investigated 
whether the heterozygous Sirt1 knockout mouse (on a sv129 background) develops diabetes. 
Untreated Sirt1 +/- mice did not develop hyperglycaemia. When treated with MLD-STZ, they became 
hyperclycaemic and reached similar blood glucose levels as wildtype littermate controls. Thus, they do 
not represent the human patients. 
Homozygous Sirt1 knockout mice are only viable on a CD1 outbred background [166]. The more 
inbred genes they contain the lower the survival rate becomes [159, 166, 167]. When our collaborator 
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Michael McBurney (University of Toronto, Canada) treated outbred homozygous Sirt1 -/- mice with 
MLD-STZ, he noticed that Sirt1 -/- displayed significantly higher blood glucose values compared to 
littermate Sirt1 +/+ and Sirt1 +/-  control mice (data not shown). Thus, there seems to be a difference 
between humans an rodents in this matter. While the heterozygous human SIRT1 L107P patients 
display inflammatory diseases, the heterozygous SIRT1 knockout mouse has no or only a faint 
phenotype [152]. This could simply be due to species differences. Another possible explanation is that 
L107P SIRT1 silences the wild type allele in humans or that L107P SIRT1 is an imprinted gene, 
meaning that only one allele is preferentially expressed. We conclude that the Sirt1 knockout mouse 
(on a sv129 background) is not a model mimicking the L107P mutation of our human patients. A more 
suitable way to characterize the molecular consequences of SIRT1 L107P could be  to create a 
knockin mouse carrying the mutated gene, a project that is in progress. 
Since the patients carry L107P heterozygously, one could treat them by activating the healthy SIRT1 
gene product. Recently, novel small-molecule activators of SIRT1 (SRTs) were described [162] and 
successfully used to treat animal models of type 2 diabetes, namely diet-induced obesity and ob/ob 
mice as well as  Zucker fa/fa rats [146] [162]. In addition, some of these compounds are currently 
under investigation in phase II clinical trials, thus their application seemed to be reasonable. We used 
these compounds to treat several animal models of type 1 diabetes. We started by investigating the 
NOD mouse, the most commonly used animal model for type 1 diabetes. This mouse spontaneously 
displays massive pancreatic immune cell infiltration and we tested if SRT treatment could diminish the 
resulting insulitis. Therefore, NOD animals were treated with 4 different SRTs with different 
potencies and concentrations, starting at the day of weaning and insulitis score (degree of immune cell 
infiltration) was measured after 2 months of treatment. None of the SRTs were able to lower the 
immune cell infiltration compared to the control group. SRT2379 and SRT501 treated mice even  
showed significantlly more periinsulitis (immune cells around pancreatic islets) than control mice. We 
conclude that these SIRT1 activators are not able to diminish immune cell infiltration indicating that   
the development of diabetes in NOD animals cannot be retarded by SRTs.  
To test this hypothesis, we initiated a diabetes prevention study in which animals were treated with the 
same protocol as in the insulitis score study. Glucosuria positive animals were subjected to blood 
glucose sampling and the development of hyperglycaemia in the different treatment groups was 
compared. None of the treament groups showed a significantly different onset of diabetes. 
Regulatory T cells (Treg) have the potential to delay the onset of diabetes [168]. Since SIRT1 was 
implicated in T cell tolerance and clonal anergy (see introduction), we investigated a potentially 
beneficial role of Tregs of SRT treated mice. We set up adoptive transfer of diabetes experiments, 
where mice were rendered diabetic by transplanting splenocytes from diabetic NOD donor mice. In 
addition, recipient mice obtained splenocytes from SRT treated mice. If SRT treatment empowered 
Tregs, the recipient mice should experience a delayed onset of diabetes. In order to obtain conclusive 
results, an animal number of at least 8 animals of the same gender per recipient group was needed. 
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Due to an accident in our animal facility, we did not have enough recipient mice of the same gender. 
Therefore, some of the experiments were performed with animals of both genders. When considering 
both female and male recipient mice, there was no delay of diabetes onset in neither of the four 
treatment groups. When considering only male recipient mice, there was a trend towards a delay in 
mice receiving Tregs from SRT2104 treated mice. But since the animal number used in this 
experiment was very low, no trustful conclusion can be drawn. Altogether, we conclude that Tregs 
from SRT treated animals are not empowered to delay the onset of diabetes in recipient mice. 
Notably, there was an unexpected accumulation of cases of death in SRT1720 and SRT501 treated 
NOD animals. This left us with too few animals to do reasonable statistics, but it also appears that 
these two SIRT1 activators do not influence the onset of diabetes. No serious in vivo side effects of 
SRT administration were so far reported in the literature and therefore these cases of death were 
unexpected but important. SRT1720 treated animals mainly died during the first 3 weeks of SRT 
administration while cases of death were observed with SRT501 treatment over the whole application 
period. 1-3 days before an individual animals was found dead in the cage, it lost weight (dorsal spine 
was extremely bony, no fat at all), animals seemed moony and inactive, started to shiver and had a 
decreased body temperature as sensed through the gloves when picked up. Rectal temperatures were 
decreased 2 days before animals died, but not enough animals were analyzed to do proper statistics. It 
is not clear if animals died because of the decreased body temperature or if the decreased body 
temperature is a consequence of the death struggle. A hint comes from Feige et al. [146] who reported 
a massive decrease in body temperature in mice dosed with SRT1720. Furthermore, they saw an 
overall increase in energy expenditure, improved lipolysis and decreased fat pad size, which was 
favourable in their obese / type 2 diabetes setting. Since the NOD mouse is a model for type 1 diabetes 
and per se very lean, this depletion of fat storage through SIRT1 activation might simply be 
deleterious because of the lack of energy or of the heat preserving fat layer. In addition, the NOD 
mouse is strongly insulin resistant and SRT administration increases insulin sensitivity [146]. The 
resulting anabolic state might further decrease availability of nutrients for energy expenditure and 
hence exacerbate maintenance of body temperature. We can exclude that these animals died because 
of mishandling. The autopsy showed no signs of incorrect gavage application. Esophagus and trachea 
were not injured. Over all, no clear cause of death could be pointed out by the pathological 
examination. Also Sirtris, the manufacturer of the SRTs, could not explain the observed cases of 
death. They claim that they never saw any side effects of these substances. We did not receive safety 
data on these SRTs, but since those substances are already in clinical trials, we have to assume that 
these side effects might be NOD specific, and may happen only in this immune compromised animal 
model. SRT titers in NOD animals were analyzed at Sirtris but they only told us that the titers were 
lower than expected without going into details. This could be due to an improper blood sampling 
timepoint (too late after SRT dosage) or due to an insufficient usage of the required inhibitor 
(Dichlorvos). In 2010, it reported that the commonly used “SIRT1 activators” resveratrol and the 
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Sirtris compounds SRT1720, SRT2183 and SRT1460 do not directly activate SIRT1. They only 
interact when a fluorophore modified substrate is present in the SIRT1 activity assay but not when a 
native substrate is present [169]. The authors were also not able to reproduce the beneficial in vivo 
effects on blood glucose and other metabolic parameters that were reported earlier with these 
compounds [146, 162]. Similar to our findings, they observed that 100 mg/kg SRT1720 was not well 
tolerated and lead to reduced food intake and death. Noteworthy, they used ob/ob animals on HFD and 
did not investigate diet-induced obese and ob/ob animals seperately, as Sirtris and their partners did. In 
addition, they reported various other interaction partners of these SRTs, including receptors, enzymes, 
ion channels, and transporters. However, one has to take into consideration that the authors are 
employees of Pfizer, which is a direct business rival of Sirtris, the manufacturer of the SRTs. Half a 
year later, a paper was published by Sirtris, providing evidence that these compounds can activate 
SIRT1 independently of the fluorophore tag [170]. They do not comment on the specificity of the 
SIRT1 activators, a point that was also critically discussed by the Pfizer report. We observed effects of 
SRT2183 in MEF SIRT-/- cells (data not shown) which supports the Pfizer finding, that some actions 
of the SRTs might be due to off-target effects. Concerning the reported positive in vivo effects of 
SRT1720, it seems unlikely that all independent researchers that published beneficial data were 
chasing a ghost. The likely explanation is that SRT1720 has desirable effects in vivo, but that these 
effects are, at least partly, not SIRT1 mediated.  
Since the NOD mouse is a rodent model for type 1 diabetes and does not necessarily represent all 
aspects of human type 1 diabetes, we decided to test another in vivo model of type 1 diabetes, the 
MLD-STZ induced diabetes mouse model. SRT1720 treatment lowered blood glucose values in 
animals that were treated with sodium acetate-solution (the solvent for stz). This is most likely due to 
the insulin-sensitising effect of SRT1720 and was reported before [146]. This effect disappeared when 
animals were treated with STZ. Both STZ groups displayed rather high glucose values and this could 
have masked an expected effect of SRT1720 treatment. Therefore, we repeated this study with 20% 
less STZ (40 mg/kg instead of 50 mg/kg). At the same time we doubled the dose of SRT1720 (200 
mg/kg instead of 100 mg/kg) because work published by Feige et al. [146] suggested that 500 mg/kg 
produces considerable effects while 100 mg/kg only slightly improves metabolic parameters. 
Unfortunately, 200 mg/kg SRT1720 in STZ treated mice had similar lethal effects as previously 
observed with 100 mg/kg in NOD mice. For ethical reasons, the experiment was stopped (data not 
shown). The reason why Feige et al. were able to use an even 2.5 fold higher dose of SRT1720 
without getting lethal effects remains elusive. Maybe the STZ treatment and the resulting catabolic 
state made our mice more susceptible. While we drug dosed our mice by daily oral gavage, Feige et al. 
mixed the drug into the food. SRT application by oral gavage might have induced a strong peak of 
SRT action while mixing the activator into the food might have lead to a mildly attenuated but 
prolonged SRT action.  
In 2011, Lee et al. reported that resveratrol-treated NOD mice were protected and rescued from 
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pancreatic insulitis and hyperglycaemia ([171]. Resveratrol is often used to activate SIRT1, even 
though its specificity is debated [169]. The authors concluded that resveratrol blocks inflammatory 
cells from migrating to the pancreas and therefore protects these animals from insulitis. As with the 
SRTs, it is not clear whether these effects are mediated by SIRT1 or if other targets lead to the 
described results.  
This study aimed to investigate potential beneficial effect of small molecular activators of SIRT1 
(SRTs) in animal models of type 1 diabetes. Further, it should have provided supportive data to initiate 
treatment of family members carrying a heterozygous mutation in SIRT1 with SRT. Results show that 
SIRT1 activation via the synthetic activators SRTs does not influence the development of 
hyperglycaemia and diabetes in the NOD and in the MLD-STZ mouse model. Further, lethal side 
effects of some of the SRTs were uncovered in these mice, strongly suggesting to reconsider the  use 
of these drugs for the treatment of the family with the SIRT1 mutation. In order to investigate whether 
SIRT1 is important in the development of diabetes, other genetic models should be used. One 
possibility is to use the SIRT1-overexpresser mouse [172]. This would circumvent the problem of 
lacking specificity as in pharmacological SIRT1 activator studies. Another way to investigate the 
impact of SIRT1 on glucose metabolism is to examine tissue specific SIRT1 knockout mice. SIRT1 
could be knocked out in β-cells in a constitutive or – in order to avoid developmental defects - in an 
inducible fashion. These and other studies will shed more light on the role of SIRT1 in the 
development of diabetes. 
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5   AMENDMENT 
5.1   Contributions 
It is rather difficult to state exactly which experiments were performed by which person, since most 
experiments were repeated several times by different researchers. In addition, we had essential help by 
our technicians Marcela Borsigova and Kirsten Rappold, who do not wish to be listed as authors in our 
publications. 
 
Person Technique Experiments 
D. T. Meier RNA profiling, GTT, ITT, harvesting organs, glucose 
uptake fat, adipose tissue size distribution, rtPCR 
(Taqman), liver lipid measurement,  GSIS, 
BMDM/BMDC isolation/differentiation, db/db 
backcrossing, genotyping, antibody injections, 
western blotting, glycogen content in muscle, writing 
manuscript, planning parts of TLR2 project and 
whole SIRT1 project, NOD breeding, testing 
glucosuria and glycaemia, staining and scoring 
insulitis, gavage, establishing MLD-STZ, 
organizing/breeding/genotyping Sirt1 +/- 
2.3.1, 2.3.2, 2.3.3, 
2.3.4, 2.3.5, 2.3.6, 
2.4.1, 2.4.2, 2.4.3, 
2.4.5, 2.4.6, 2.4.8, 
3.3.1, 3.3.2, 3.3.3, 
3.3.4, 3.3.5 
J. A. Ehses GTT, ITT, harvesting organs, GSIS, BMDM/BMDC 
isolation/differentiation, luminex, teaching 
techniques, writing manuscript, planning and 
supervising TLR2 project  
2.3.1, 2.3.2, 2.3.3, 
2.3.4, 2.3.5, 2.4.1, 
2.4.2, 2.4.4, 2.4.8, 
2.4.9 
M. Böni-Schnetzler Teaching techniques, supervising SIRT1 project, 
giving input on all projects, correcting thesis  
 
Marc Y. Donath Organizing funds, supervising SIRT1 project, giving 
input on all projects, correcting thesis 
 
M. Borsigova RNA profiling, GTT, ITT, harvesting organs, glucose 
uptake fat, adipose tissue size distribution, rtPCR 
2.3.1, 2.3.2, 2.3.3, 
2.3.4, 2.3.5, 2.4.1, 
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(Taqman), liver lipid measurement, 
Immunohistochemistry, GSIS, BMDM/BMDC 
isolation/differentiation 
2.4.2, 2.4.4, 2.4.8, 
2.4.9, 3.3.2 
K. Rappold Animal handling, weaning, cutting biopsies, gavage, 
measuring glucosuria and glycaemia 
3.3.1, 3.3.2, 3.3.3, 
3.3.4 
C. Boitard Input (NOD experiments)  
S. Wueest clamping 2.3.3, 2.4.7 
J. Rytka clamping 2.3.3, 2.4.7 
P. Y. Wielinga Indirect colorimetry, activity determination 2.3.2 
H. Esterbauer congenics Discussion  
O. Tschopp Muscle triacylglycerols  2.4.6 
S. M. Schultze Muscle triacylglycerols 2.4.6 
U. Malipiero Taught how to isolate/differentiate BMDM/BMDC 2.3.5 
H. Ellingsgaard support splenocyte preparation for adoptive transfer 3.3.3 
F. C. Schuit gene array 2.3.1 
D. Konrad input and suggestions  
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